Patient is not a candidate for stem cell transplant due to advanced age or co-morbidities; or the enrollee does not have donor available; or the enrollee declines stem cell transplant due to personal belief; or stem cell transplant is not standard of care based on the risk category of diseaseXx_NEWLINE_xXMust not have received any prior stem cell transplantXx_NEWLINE_xXStem cell infusions (with or without total body irradiation [TBI]):\r\n* Allogeneic (non-autologous) bone marrow or stem cell transplant, or any stem cell infusion including donor lymphocyte infusion (DLI) or boost infusion: >= 84 days after infusion, and no evidence of graft-versus-host disease (GVHD)\r\n* Autologous stem cell infusion including boost infusion: >= 42 daysXx_NEWLINE_xXStem cell Infusion without TBI: no evidence of active graft vs host disease and at least 84 days must have elapsed after transplant or stem cell infusionXx_NEWLINE_xXSTEP II: Patients must not have received any non-protocol therapy outside of the assigned induction therapy including stem cell transplantXx_NEWLINE_xXPatients must meet institutional eligibility requirements for stem cell transplant, including cardiac, renal, liver, and pulmonary requirementsXx_NEWLINE_xXStem cell transplant or rescue: patient has not had a prior stem cell transplant or rescueXx_NEWLINE_xXPatients must not be candidates for allogeneic hematopoietic stem cell transplant; NOTE: Subjects up to age 70 years who are considered fit for allogeneic hematopoietic stem cell transplant, should be considered for enrollment on E1910, in order to avoid competing with that study; if a patient is considered unfit for intensive chemotherapy at the time of initial diagnosis, but subsequently achieves a complete remission (CR), then it will be left to the treating physician’s discretion to consider hematopoietic stem cell transplant (HSCT)Xx_NEWLINE_xXPatients who have had a prior allogeneic stem cell transplant are not eligible\r\n* NOTE: if a patient underwent auto SCT, he/she must demonstrate engraftment (per treating investigator’s discretion) and meet all other hematological requirementsXx_NEWLINE_xXPatient must not have received any prior marrow-ablative chemotherapy and autologous hematopoietic cell transplantXx_NEWLINE_xXELIGIBILITY CRITERIA - PHASE I (ARMS A, B, C): Patient may be enrolled with a prior allogeneic hematopoietic stem cell transplant (HSCT) but the transplant date must be at least 90 days before date of enrollment; patient must be off immunosuppression and without active graft versus host disease (GVHD) prior to enrollment if previous HSCTXx_NEWLINE_xXELIGIBILITY CRITERIA - PHASE II (ARM D): Patient may be enrolled with a prior allogeneic hematopoietic stem cell transplant (HSCT) but the transplant date must be at least 90 days before date of enrollment; patient must be off immunosuppression and without active GVHD prior to enrollment if previous HSCTXx_NEWLINE_xXAutologous stem cell transplantXx_NEWLINE_xXSubjects who are considered eligible to receive an autologous stem cell transplantXx_NEWLINE_xXPrior allogeneic stem cell transplantXx_NEWLINE_xXStem cell transplant (autologous or allogeneic) within 100 days of study treatment startXx_NEWLINE_xXGene therapy using an integrating vector Allogeneic hematopoietic stem cell transplant at any time not permittedXx_NEWLINE_xXPrior peripheral stem cell transplant within 12 weeks of randomizationXx_NEWLINE_xXIneligible for hematopoietic stem cell transplant.Xx_NEWLINE_xXAllogeneic stem cell transplant within the last 6 months, or autologous stem cell transplant within the last 3 months before the date of study treatment administration.Xx_NEWLINE_xXPatients who have received prior allogeneic stem cell transplantXx_NEWLINE_xXStem cell transplant or rescue: no evidence of active graft versus (vs.) host disease and ? 2 months must have elapsed since transplant prior to registrationXx_NEWLINE_xXB-cell lymphoma patients who have received prior allogeneic stem cell transplantXx_NEWLINE_xXHematopoietic stem cell transplant =< 3 months prior to registrationXx_NEWLINE_xXAllogeneic stem cell transplant within 100 days before first dose of study drugXx_NEWLINE_xXHas had a prior stem cell or bone marrow transplant.Xx_NEWLINE_xXPatients who completed single autologous stem cell transplant after completion of at most 2 induction regimens (excluding dexamethasone alone) and are in at least stable disease compared to pre-induction in the first 100 days after stem cell transplantationXx_NEWLINE_xXPatient must be >= 3 months since high dose chemotherapy and peripheral blood stem cell rescue prior to registrationXx_NEWLINE_xXAutologous stem cell transplant following myeloablative therapy within 3 months prior to the first dose of abemaciclib or prior allogeneic stem cell transplant at any time; patients who received stem cell reinfusion following non-myeloablative therapy are eligible once they meet peripheral blood count criteriaXx_NEWLINE_xXAllogeneic stem cell transplant patients and any patient who has relapsed within 100 days of stem cell infusion following an autologous bone marrow transplant.Xx_NEWLINE_xXPatients must not have received allogeneic stem cell transplantXx_NEWLINE_xXStem cell infusion without TBI: no evidence of active graft versus host disease and at least 84 days must have elapsed after transplant, and 42 days for autologous stem cell infusion after I^131-MIBG therapyXx_NEWLINE_xXPrevious high-dose chemotherapy requiring stem cell rescue.Xx_NEWLINE_xXAutologous hematologic stem cell transplant within 3 months of study entry; allogeneic hematologic stem cell transplant within 6 months; grade II, or greater, active graft-versus-host diseaseXx_NEWLINE_xXStem cell transplant less than 3 months prior to enrolment.Xx_NEWLINE_xXPrior peripheral stem cell transplant within 12 weeks of the first dose of study treatmentXx_NEWLINE_xXPrior allogeneic hematopoietic cell transplantXx_NEWLINE_xXAny prior allogeneic hematopoietic stem cell or solid organ transplant.Xx_NEWLINE_xXHas received an allogeneic bone marrow or allogeneic stem cell transplant.Xx_NEWLINE_xXStem Cell Transplant (SCT): No evidence of active graft versus host disease. For allogeneic SCT, greater than or equal to 6 months must have elapsed.Xx_NEWLINE_xXPatients are not eligible if they have had or are planned for solid organ transplant or allogeneic hematopoietic stem cell transplantXx_NEWLINE_xXPrevious allogeneic stem cell transplantXx_NEWLINE_xXPrior high dose chemotherapy requiring stem cell rescue.Xx_NEWLINE_xXWho have received autologous stem cell transplant (SCT) 60 days before first infusion of TAK-573 or participants who have received allogeneic SCT 6 months before first infusion. Graft-versus-host disease that is active or requires ongoing systemic immunosuppression.Xx_NEWLINE_xXPrevious high-dose chemotherapy requiring allogenic stem cell rescue.Xx_NEWLINE_xXPrior allogeneic stem cell or solid organ transplantXx_NEWLINE_xXRecipients of prior autologous hematopoietic stem cell transplantation are ineligible if disease recurrence occurred less than 6 months from their autologous stem cell transplant.Xx_NEWLINE_xXBCL6+ DLBCL: patients must have disease that has relapsed and or is refractory to prior therapy, which must have included an anthracycline, if not contraindicated; patients must have relapsed following or be ineligible for, or refuse, autologous stem cell transplantXx_NEWLINE_xXHas undergone solid organ transplant at any time, or prior allogeneic hematopoietic stem cell transplantation within the last 5 years. (Participants who have had an allogeneic hematopoietic transplant >5 years ago are eligible as long as there are no symptoms of Graft Versus Host Disease [GVHD].)Xx_NEWLINE_xXCompleted allogeneic stem cell transplant (allo-SCT) or are eligible for and willing to complete allo-SCTXx_NEWLINE_xXUndergone an allogeneic stem cell transplant within the past 1 yearXx_NEWLINE_xXPrior allogeneic stem cell transplant.Xx_NEWLINE_xXIntention to proceed to high dose chemotherapy (HDT) and autologous hematopoietic stem cell transplant (HSCT)Xx_NEWLINE_xXPatients with relapsed or refractory classical HL who have previously received autologous stem cell transplant (ASCT); patients must have received prior ASCT at least 12 weeks (3 months) before the first dose of ibrutinib or patients with relapsed or refractory HL who have failed at least 2 lines of prior therapy and are not eligible for ASCT due to:\r\n* Inability to achieve a complete response (CR) or partial response (PR) prior to transplant\r\n* Age or comorbid conditions\r\n* Inability to collect stem cellsXx_NEWLINE_xXPrior allogeneic stem cell transplantXx_NEWLINE_xXrelapse within 1 year from frontline chemo-immunotherapy and ineligible for autologous hematopoietic stem cell transplant (auto-HSCT)Xx_NEWLINE_xXReceipt of previous allogeneic stem cell transplant; receipt of previous autologous transplant for AML or non-AML condition is allowedXx_NEWLINE_xXAutologous or allogeneic stem cell or bone marrow transplant within 3 months prior to cycle 1 day 1Xx_NEWLINE_xXPatients must have completed an autologous stem cell transplant after their first course of treatment; patients who have relapsed or progressed at any time prior to transplant are not eligibleXx_NEWLINE_xXStem Cell Transplant or Rescue: No evidence of active graft vs. host disease and ? 2 months must have elapsed since transplant.Xx_NEWLINE_xXPrevious allogeneic stem cell transplantXx_NEWLINE_xXUndergoing stem cell transplant at Center for Cell and Gene Therapy (CAGT)Xx_NEWLINE_xXLess than 30 days post-allogeneic stem cell transplantXx_NEWLINE_xXDonors for allogeneic (i.e. HLA matched or mismatched related or unrelated) stem cell transplants who have fulfilled eligibility for and consented to stem cell donation as per the stem cell transplant program's standard operating proceduresXx_NEWLINE_xXUndergoing stem cell transplant at Center for Cell and Gene Therapy (CAGT)Xx_NEWLINE_xXDonors for allogeneic (i.e. human leukocyte antigen [HLA] matched or mismatched related or unrelated) stem cell transplants who have fulfilled eligibility for and consented to stem cell donation as per the stem cell transplant program's standard operating proceduresXx_NEWLINE_xXLess than 30 days post-allogeneic stem cell transplantXx_NEWLINE_xXHistory of bone marrow transplant and stem cell rescueXx_NEWLINE_xXPrior allogeneic stem cell or solid organ transplantXx_NEWLINE_xXPrior autologous stem cell transplant ? 3 months prior to starting CC-90002.Xx_NEWLINE_xXPrior allogeneic stem cell transplant with either standard or reduced intensity conditioning ? 6 months prior to starting CC-90002.Xx_NEWLINE_xXPatients must have received an allogeneic stem cell transplant for a hematologic malignancyXx_NEWLINE_xXPatient must be >= 12 weeks since autologous bone marrow/stem cell transplant prior to enrollmentXx_NEWLINE_xXINCLUSION CRITERIA FOR STRATUM C: Patient must be:\r\n* >= 12 weeks since autologous bone marrow/stem cell transplant prior to enrollment\r\n* >= 5 years since allogeneic bone marrow transplant prior to enrollment with no evidence of active graft versus (vs.) host diseaseXx_NEWLINE_xXPrevious bone marrow or stem cell transplantXx_NEWLINE_xXHas received an allogeneic stem cell transplantXx_NEWLINE_xXPatients who have undergone autologous stem cell transplant > 6 months prior are eligibleXx_NEWLINE_xXPatients who have undergone allogeneic stem cell transplant > 12 months, without active graft-versus-host-disease, and not on immunosuppression for prevention of graft-versus-host disease are eligibleXx_NEWLINE_xXPatients who have underwent autologous or allogeneic stem cell transplant =< 4 weeks prior to cycle 1 day 1 or have active graft-versus-host disease are excludedXx_NEWLINE_xXPatients must have histologically confirmed relapsed or refractory non-Hodgkin’s lymphoma or Hodgkin’s lymphoma (World Health Organization [WHO] criteria), for which they are unwilling or unable to undergo an autologous stem cell transplant; patients may have relapsed after prior stem cell transplantXx_NEWLINE_xXOne or more prior lines of chemoimmunotherapy and/or monotherapy with rituximab or other anti-cluster of differentiation (CD)20 antibody; patients may have had a prior autologous stem cell transplant but not prior allogeneic stem cell transplantationXx_NEWLINE_xXPrior autologous or allogeneic stem cell transplant (SCT)Xx_NEWLINE_xXThere is no upper limit for the number of prior therapies; patients may have relapsed after prior autologous or allogeneic stem cell transplantXx_NEWLINE_xXSubjects with a prior history of stem cell transplant (autologous and/or allogeneic) are allowed ifXx_NEWLINE_xXPatients with systemic T cell lymphomas who relapsed after autologous transplant are eligibleXx_NEWLINE_xXPrior allogeneic hematopoietic cell transplantXx_NEWLINE_xXSubjects with a history of autologous or allogenic stem cell transplantation must have adequate peripheral blood counts independent of any growth factor support, and have recovered from any transplant related toxicity(s) and be at least 100 days post-autologous transplant prior to first dose of study drug or at least 6 months post-allogenic transplant prior to first dose of study drug and not have active graft-versus-host disease (GVHD), i.e., requiring treatment.Xx_NEWLINE_xXDisease must be refractory to conventional induction therapy or relapsed after initial standard therapy for ALL; any number of prior therapies is permitted and including allogeneic and/or autologous stem cell transplantXx_NEWLINE_xXPrevious allogeneic hematopoietic stem cell transplantXx_NEWLINE_xXFor subjects with prior allogeneic stem cell transplant, no evidence of active graft-versus host disease (GVHD), and must be >= 2 weeks off immunosuppressive therapyXx_NEWLINE_xXPrior allogeneic hematopoietic stem cell transplantsXx_NEWLINE_xXAllogeneic hematopoietic stem cell transplantXx_NEWLINE_xXPrior allogeneic stem cell or solid organ transplant;Xx_NEWLINE_xXIf prior allogeneic stem cell transplant, history of moderate to severe chronic graft versus host disease (GVHD)Xx_NEWLINE_xXPrior first allogeneic stem cell transplant, with any graft source, donor type, and GVHD prophylaxisXx_NEWLINE_xXPrior peripheral stem cell transplant within 12 weeks of initiation of therapyXx_NEWLINE_xXPatients with active graft-versus-host-disease (GVHD) status post stem cell transplant, i.e. patients requiring therapy more than chronic steroid immunosuppression and/or phototherapy for chronic skin GVHD will be excluded.Xx_NEWLINE_xXAllogeneic stem cell transplant within the past 1 yearXx_NEWLINE_xXPrior autologous stem cell transplant within 6 months of screening dateXx_NEWLINE_xXStem cell transplant recipients must have no evidence of active graft-versus-host diseaseXx_NEWLINE_xXHistory of organ or hematopoietic stem cell transplant.Xx_NEWLINE_xXPrior allogeneic stem cell transplant within 6 months of study drug administration and no requirement for graft versus host therapy.Xx_NEWLINE_xXCohort #2: patients with MCL with prior allogeneic hematopoietic stem cell transplant, minimum 6 months after transplant, not on immunosuppression, and without prior or active graft versus host disease (GVHD), are allowedXx_NEWLINE_xXPatients who are not hematopoietic stem cell transplant candidates are excluded for the DLBCL cohort (cohort #1)Xx_NEWLINE_xXHistory of allogeneic stem cell transplant.Xx_NEWLINE_xXTwo prior stem cell transplants of any kind.Xx_NEWLINE_xXOne prior autologous stem cell transplant within the preceding 12 months.Xx_NEWLINE_xXOne prior allogeneic stem cell transplant within the preceding 24 months.Xx_NEWLINE_xXPatients who have received prior allogeneic stem cell transplant will be permitted to enroll on the protocolXx_NEWLINE_xXPatients with systemic T cell lymphomas who relapsed after autologous transplant are eligibleXx_NEWLINE_xXPrior allogeneic stem cell transplant is not permittedXx_NEWLINE_xXPrior organ transplant including allogenic hematopoietic stem cell transplantXx_NEWLINE_xXStem cell transplantation: Previously received an allogenic stem cell transplant; and/or received an autologous stem cell transplant less than or equal to (<=) 12 weeks before the first dose of study drugXx_NEWLINE_xXHistory of allogeneic stem cell transplantXx_NEWLINE_xXRelapsed or refractory to prior standard therapy and subjects who are not candidates for high-dose therapy or autologous stem cell transplantXx_NEWLINE_xXAutologous hematologic stem cell transplant within 6 months of study entry. Prior Allogeneic hematologic stem cell transplant is excludedXx_NEWLINE_xXRelapsed or refractory disease after allogeneic transplant provided subject is at least 100 days from stem cell transplant at the time of enrollmentXx_NEWLINE_xXPrevious high-dose chemotherapy requiring stem cell rescueXx_NEWLINE_xXPrior allogeneic stem cell transplant or organ graftXx_NEWLINE_xXPrior stem cell transplant.Xx_NEWLINE_xXPrior autologous stem cell transplant within 6 months of study entryXx_NEWLINE_xXHematopoietic stem cell transplant comorbidity index (HCT-CI) >= 3^50Xx_NEWLINE_xXPatients within 1 year of allogeneic stem cell transplant, patients with active graft versus host disease (GVHD) or requiring immunosuppression are excludedXx_NEWLINE_xXBone marrow transplant or stem cell rescueXx_NEWLINE_xXAt least 9 months from stem cell transplant with no active graft versus host diseaseXx_NEWLINE_xXUndergoing autologous stem cell transplant for one of the following diagnoses:\r\n* Multiple myeloma\r\n* Non-Hodgkin lymphomaXx_NEWLINE_xXSubject has been informed of the risks and benefits of intensive chemotherapy and autologous stem cell transplant for treatment of mantle cell lymphoma and has refused this option; this discussion must be clearly documented in the medical record at the time of enrollmentXx_NEWLINE_xXPatients whom have undergone previous autologous stem cell transplant, and have recurrent or residual disease are eligible for this trialXx_NEWLINE_xXPrior allogeneic stem cell or solid organ transplantXx_NEWLINE_xXRelapsed and/or refractory disease as defined by: a. Clonal relapse after at least one previous line of therapy or high-dose chemotherapy and autologous stem cell transplantation OR b. Refractory disease to prior therapy defined as less than a hematologic very good partial response (VGPR). If previous therapy was autologous stem cell transplant (SCT), must be >= 3 months after SCTXx_NEWLINE_xXReceived autologous stem cell transplant within 12 weeks before the date of randomization, or the participant has previously received allogeneic stem cell transplant (regardless of timing)Xx_NEWLINE_xXPlans to undergo a stem cell transplant prior to progression of disease on this study (these participants should not be enrolled to reduce disease burden prior to transplant)Xx_NEWLINE_xXHistory of stem cell transplant.Xx_NEWLINE_xXSubjects must be at least 100 days from prior stem cell transplant (autologous or allogeneic) or donor lymphocyte infusion (DLI)Xx_NEWLINE_xXPrior radiation: Cranial irradiation, total body irradiation (TBI), or ? 50% radiation of pelvis ? 3 months prior to screening. Focal irradiation: ? 3 weeks prior to screening if radiation field involved a nontarget lesion; ? 6 weeks prior to screening if radiation field involved a target lesion. Note: True disease progression following prior irradiation therapy must be confirmed by Investigator prior to screening. • Bone marrow transplant: < 6 months since allogeneic bone marrow transplant prior to screening. < 3 months since autologous bone marrow/stem cell transplant prior to screening. < 3 months since stem cell transplant (SCT) or Rescue without TBI with no evidence of GVHD prior to screening. • Radioisotopes: fluorothymidine (18FLT) ? 72 hours prior to first dose of study drugXx_NEWLINE_xXOne or two prior lines of therapy (defined as either one non-transplant regimen such as MelDex, Vel-Dex or CyBorD, daratumumab, one autologous stem cell transplant, or one regimen of non-transplant induction therapy followed by a single autologous stem cell transplant (without hematologic progression between induction and autologous stem cell transplant [ASCT])Xx_NEWLINE_xXPrior autologous stem cell transplant within 12 weeks of initiation of therapyXx_NEWLINE_xXNo evidence of active graft-versus-host disease (GVHD) and at least 100 days must have elapsed after allogeneic bone marrow transplant or stem cell infusion prior to study drug administrationXx_NEWLINE_xXAllogeneic stem cell transplant within the last 6 months, or autologous stem cell transplant within the last 3 months before the date of first dose of study treatment.Xx_NEWLINE_xXPatients are eligible > 100 days after autologous stem cell infusion following myeloablative therapy; patients receiving an autologous stem cell infusion to support non-myeloablative therapy (including 131iodine [I]-MIBG given as a single agent) are eligible >= 6 weeks following the stem cell infusion provided they meet the hematologic and other organ function criteria for eligibility; patients who have received an allogeneic stem cell transplant are excludedXx_NEWLINE_xXPrior allogeneic bone marrow- or stem cell-transplantXx_NEWLINE_xXrelapse within 1 year from frontline chemo-immunotherapy and ineligible for autologous hematopoietic stem cell transplant (auto-HSCT)Xx_NEWLINE_xXPrior allogeneic stem cell transplantXx_NEWLINE_xXHas received a prior allogeneic hematopoietic stem cell transplant within the past 5 years, requires immunosuppression, or has evidence of active graft-versus-host-diseaseXx_NEWLINE_xXHas received prior autologous hematopoietic stem cell transplant within the last 60 daysXx_NEWLINE_xXPrior allogeneic stem cell or solid organ transplantXx_NEWLINE_xXPatients who have undergone allo-stem cell transplant (SCT) are eligible if they are at least 3 months post SCT, have relapsed AML, are not on treatment or prophylaxis for graft versus host disease (GVHD), and have no active GVHD.Xx_NEWLINE_xXDiagnosed with high risk hematologic disorders warranting stem cell transplant per institutional standard of careXx_NEWLINE_xXPrior hematopoietic stem cell transplant for AMLXx_NEWLINE_xXPatients with any hematologic malignancy undergoing either an unmodified allogeneic HCT or a double umbilical cord blood transplant with or without the infusion of T-cell depleted HLA-haploidentical peripheral blood stem cellsXx_NEWLINE_xXAfter failure of allogeneic stem cell transplant (ASCT) or after failure of frontline therapy in subjects who declined or are not ASCT candidatesXx_NEWLINE_xXPrior stem cell transplantXx_NEWLINE_xXHistory of immunosuppression or autoimmunity, including human immunodeficiency virus (HIV), and organ or stem cell transplant, or an autoimmune condition previously treated with immunosuppressive therapyXx_NEWLINE_xXPatients with ALL, CLL, NHL with relapsed disease following standard therapy or a stem cell transplant.Xx_NEWLINE_xXReceived an allogeneic stem cell transplant in the past 1 year (if over 1 year post allogeneic transplant, must not have active chronic graft versus host disease [cGVHD])Xx_NEWLINE_xXAllogeneic stem cell transplant within the last 6 months, or active graft-versus-host disease following allogeneic transplant or autologous stem cell transplant within the last 3 months before the date of the first dose of study drug administration.Xx_NEWLINE_xXPatients who have received autologous stem cell transplant (ASCT) =< 12 weeks prior to the first dose of study drugXx_NEWLINE_xXHistory of autologous or allogeneic stem cell transplantXx_NEWLINE_xXPlanned stem cell transplant during the first 6 cycles of protocol therapy are excluded. Stem cell collection during the first 6 cycles of protocol therapy is permittedXx_NEWLINE_xXBe a recipient of hematopoietic stem cell transplant.Xx_NEWLINE_xXEligible for high-dose therapy and autologous stem-cell rescueXx_NEWLINE_xXComorbid condition(s) which, in the opinion of the attending physician and/or MSK Cancer Center (CC) principal investigator, will preclude stem cell mobilization and/or high-dose therapy with autologous stem cell rescueXx_NEWLINE_xXPrior allogenic stem cell or solid organ transplantXx_NEWLINE_xXPHASE I: Histologically confirmed classical or lymphocyte predominant Hodgkin’s disease that is relapsed or refractory after at least one prior chemotherapy; patients who have not had prior high-dose therapy (HDT)/autologous stem cell transplant (ASCT) must be ineligible for transplantXx_NEWLINE_xXPHASE I: Patients must have received at least one prior therapy; prior autologous stem cell transplant is permitted; patients with DLBCL who have not had prior HDT/ASCT must be ineligible for transplant; prior lenalidomide is not permitted if patients have progressed on therapyXx_NEWLINE_xXPHASE IB DOSE EXPANSION: Patients must have received at least one prior therapy; prior autologous stem cell transplant is permitted; patients who have not had prior HDT/ASCT must be ineligible for transplant; prior lenalidomide is not permitted if patients have progressed on therapyXx_NEWLINE_xXPHASE II: Patients must have received at least one prior therapy; prior autologous stem cell transplant is permitted; patients with DLBCL who have not had prior HDT/ASCT must be ineligible for transplant; prior lenalidomide is not permitted if patients have progressed on therapyXx_NEWLINE_xXPatients who are hematopoietic stem cell transplant candidates are excludedXx_NEWLINE_xXStem cell transplant recipients must have no evidence of and not receive treatment for graft-versus-host diseaseXx_NEWLINE_xXAt least one prior therapy; prior autologous stem cell transplant is permitted; patients with aggressive lymphoma who have not received high-dose therapy (HDT)/autologous stem cell transplantation (ASCT) must be ineligible for HDT/ASCT; prior allogeneic stem cell transplant is not permittedXx_NEWLINE_xXPrior allogeneic stem cell transplant is not permittedXx_NEWLINE_xXPatients who are < 90 days post allogeneic stem cell transplant will be excluded; patients beyond 90 days post-allogeneic stem cell transplant with active uncontrolled graft versus host disease (GVHD) > grade 1 will be excluded; patients who are on a stable dose of immunosuppressive therapy (tacrolimus, cyclosporine, or other) for > 2 weeks will be eligible but those with recent increase in the immunosuppressive medication dose within last 2 weeks to control GVHD will not be included; Note: subjects may be using systemic corticosteroids or topical or inhaled corticosteroids post allogeneic stem cell transplant; patients requiring >= 1 mg/kg prednisone for GVHD management at the time of screening will not be eligible until the prednisone can be weaned to < 1 mg/kg; such patients should be monitored for at least 14 days and if no flare of GVHD requiring re-escalation of steroids or additional interventions for the GVHD they will be eligibleXx_NEWLINE_xXPART I: Patients must have received at least one prior therapy; prior autologous stem cell transplant is permitted; patients with DLBCL who have not had prior high-dose therapy (HDT)/autologous stem cell transplant (ASCT) must be ineligible for transplant; prior ibrutinib is not permitted if patients have progressed on therapyXx_NEWLINE_xXPART IB: Patients must have received at least one prior therapy; prior autologous stem cell transplant is permitted; patients with DLBCL who have not had prior HDT/ASCT must be ineligible for transplant; prior ibrutinib is not permitted if patients have progressed on therapyXx_NEWLINE_xXPrior hematopoietic stem cell transplant for the diagnosis of MDSXx_NEWLINE_xXPatients with previous allogeneic stem cell transplant (SCT) if they meet either of the following criteria:\r\n* =< 60 days from allogeneic SCT \r\n* Active acute or chronic graft-versus-host-disease (GvHD) or receiving immunosuppressive therapy as treatment for GvHDXx_NEWLINE_xXSubjects are not a candidate, or have failed allogeneic stem cell transplantation. Subjects who underwent allo-transplant in the past are eligible under following conditions: transplant was >2 year prior to enrolment, and no evidence of active graft-versus-host disease (GVHD)Xx_NEWLINE_xXHave been informed of other treatment options and is not a candidate for standard treatment options or stem cell transplant at the time of enrollmentXx_NEWLINE_xXAutologous hematologic stem cell transplant within 3 months of study entryXx_NEWLINE_xXAllogeneic hematologic stem cell transplant within 12 months of study entryXx_NEWLINE_xXMust have received front-line chemotherapy; no upper limit for the number of prior therapies; patients may have relapsed after prior autologous stem cell transplant or allogeneic stem cell transplantXx_NEWLINE_xXPatients with histologically confirmed multiple myeloma that are being considered for high dose chemotherapy and autologous stem cell transplantXx_NEWLINE_xXPatients with previous allogeneic stem cell transplant (SCT) are excluded within 6 months or with active acute or chronic graft-versus host disease are excluded; patients must be off immunosuppression for graft versus host disease (GVHD) for at least 30 days before cycle 1 dayXx_NEWLINE_xXPrior allogeneic stem cell transplantXx_NEWLINE_xXPrevious allogeneic hematopoietic cell transplant (HCT)Xx_NEWLINE_xXHistory of hematopoietic stem cell transplant (HSCT)Xx_NEWLINE_xXHas previously received an allogeneic hematopoietic cell transplant or chimeric antigen receptor-modified (CAR)-T cellsXx_NEWLINE_xXHodgkin's disease (HD): Induction failures, after first complete remission, or relapse (including relapse post autologous hematopoietic stem cell transplant), or those with active diseaseXx_NEWLINE_xXEligible and willing to proceed with an allogeneic stem cell transplant with an acceptable stem cell donorXx_NEWLINE_xXPRIOR TO CELL PROCUREMENT: Diagnosis of recurrent HL or NHL in patients who have failed > 2 prior treatment regimens; patients relapsed after autologous or allogeneic stem cell transplant are eligible for this studyXx_NEWLINE_xXHas had an allogeneic stem cell transplant with current active graft-versus-host-disease.Xx_NEWLINE_xXPrior allogeneic stem cell transplantXx_NEWLINE_xXAny autologous patient who underwent high dose melphalan (>= 140 mg/m^2) therapy/peripheral blood stem cell (PBSC) rescue for any stage of multiple myeloma and did not participate in another clinical transplant trial whose primary endpoint is also evaluating long-term, disease-free survival or survival; consenting for study between 30 days to 120 days after transplant; earliest can start therapy is 30 days post transplant after recovered from acute toxicity of autologous stem cell transplant (ASCT)Xx_NEWLINE_xXPrior allogeneic transplants is allowed prior to study start (1st dose of study medication), but patients must also be at least 6 months from date of stem cell infusion, have no evidence of graft versus host disease (GVHD), be off all immunosuppressant medications, and have recovered to =< grade 1 toxicities related to this procedureXx_NEWLINE_xXSubjects must be at least 90 days since autologous stem cell transplant, if performedXx_NEWLINE_xXPrior allogeneic hematopoietic cell transplant.Xx_NEWLINE_xXNo further chemotherapy or stem cell transplant (SCT) planned at the time of enrollmentXx_NEWLINE_xXHas received allogeneic hematopoietic stem cell transplant within 3 months of CAR T cell infusion; hematopoietic stem cell transplant (HSCT) > 3 months from CAR T cell infusion eligibleXx_NEWLINE_xXPatient must be ? 3 months from hematopoietic stem cell transplant, must not have active GVHD, and must be off all immunosuppressionXx_NEWLINE_xXPrior autologous stem cell transplant (SCT) in the prior 12 monthsXx_NEWLINE_xXPrior stem cell transplant except of patients with neuroblastoma, lymphoma or myelomaXx_NEWLINE_xXMust have a confirmed diagnosis of DLBCL and have progressed following ?2 lines of previous therapy, after autologous stem cell transplant, or not a candidate for autologous stem cell transplantXx_NEWLINE_xXHave undergone autologous or allogeneic stem cell transplant <60 days prior to receiving the first dose of ponatinib; have any evidence of ongoing graft-versus-host disease (GVHD) or GVHD requiring immunosuppressive therapy or are being considered for stem cell transplant within 6-12 months of enrollment (note: ponatinib is not to be used as a bridge to stem cell transplant in this trial)Xx_NEWLINE_xXPatients with prior hematopoietic stem cell transplant (HSCT) are eligible, with the exception of the following:\r\n* Autologous HSCT within 60 days of study entry\r\n* Allogeneic HSCT within 90 days of study entry\r\n* Evidence of graft-versus-host-disease (GVHD)\r\n* Treatment with immunosuppressive medications within 14 days; however, weaning or stable doses of steroids (must be =< 20 mg/m^2/day of prednisone equivalents) and/or calcineurin inhibitors are permittedXx_NEWLINE_xXAutologous stem cell transplant within 6 weeks before enrollment or any history of allogenic transplantXx_NEWLINE_xXPatients must be relapsed or are refractory to at least 3 prior lines of therapy, including both a proteasome inhibitor an immunomodulatory drug (IMiD), and for whom a transplant is not recommended (induction therapy and stem cell transplant +/- maintenance will be considered as one regimen)Xx_NEWLINE_xXHematologic Malignancy\r\n* No human leukocyte antigen (HLA) identical sibling or suitable unrelated donor, or time needed to find an acceptable unrelated donor match would likely result in disease progression such that the patient may become ineligible for any type of potentially curative transplant\r\n* Relapsed or primary therapy-refractory acute myeloid leukemia (AML) with bone marrow blast < 20%\r\n* High-risk refractory or relapsed acute lymphoblastic leukemia (ALL) in patients for whom transplantation is deemed indicated (relapse occurring < 30 months from diagnosis, patients relapsing after previous allogeneic transplant, relapse after 2nd remission, primary induction failure or hypodiploidy)\r\n* Patients with relapsed Hodgkin lymphoma unable to achieve 2nd remission or very good partial remission (VGPR) and therefore ineligible to receive autologous stem cell transplantation\r\n* Patients with Hodgkin lymphoma relapsing after autologous stem cell transplant\r\n* Patients with primary refractory or relapsed non-Hodgkin lymphoma (NHL) unable to achieve 2nd remission or very good partial remission (VGPR) and therefore ineligible to receive autologous stem cell transplantation\r\n* Patients with NHL relapsing after autologous stem cell transplant\r\n* Patients with myelodysplastic syndrome (MDS)/myeloproliferative syndrome (MPS)Xx_NEWLINE_xXAutologous stem-cell transplant in the previous six monthsXx_NEWLINE_xXPrior bone marrow or stem cell transplantXx_NEWLINE_xXPatients with the diagnosis of severe AA, who are not currently candidates for an allogeneic stem cell transplant, fulfilling the following criteria:Xx_NEWLINE_xXPatients with previous allogeneic stem cell transplant (SCT) within 6 months or with active acute or chronic graft-versus host disease are excluded; patients must be off immunosuppression for graft-versus host disease (GVHD) for at least 30 days before cycle 1 day 1Xx_NEWLINE_xXRecovered (i.e., =< grade 1 toxicity) from the reversible effects of autologous stem cell transplantXx_NEWLINE_xXPatients having undergone prior allogeneic stem cell transplant within 3 months or having active graft versus host diseaseXx_NEWLINE_xXThe patient must have no evidence of active graft vs. host disease, and greater than or equal to 12 weeks must have elapsed since transplant or stem cell infusion and enrollment on this study for any other pathologyXx_NEWLINE_xXARM 2 SALVAGE COHORT: Patients with AML who have failed up to one prior salvage therapy (i.e. salvage 1 or 2 status) will be eligible for Arm 2 relapse cohort; allogeneic stem cell transplant for patients in remission at the time of stem cell transplant will not be considered a salvage regimen; similarly, hydroxyurea if used alone will not be considered a salvage regimenXx_NEWLINE_xXStem cell transplant (SCT): at least 8 weeks following autologous SCT and 12 weeks for allogeneic SCTXx_NEWLINE_xXPatients who have received a prior stem cell transplantXx_NEWLINE_xXNo evidence of active graft vs. host disease and at least 84 days must have elapsed after transplant or stem cell infusion.Xx_NEWLINE_xXPatients had prior autologous or allogeneic stem cell transplant; prior stem cell collection is allowedXx_NEWLINE_xXReceipt of hematopoietic stem cell transplant (HSCT) within 60 days of the first dose of TAK-659; clinically significant graft-versus-host disease (GVHD) requiring ongoing immunosuppressive therapy post HSCT at the time of screening (use of topical steroids for ongoing skin GVHD is permitted).Xx_NEWLINE_xXPatients with previous allogeneic stem cell transplant (SCT) if they meet either of the following criteria:\r\n* < 100 days from allogeneic SCT\r\n* Active acute or chronic graft-versus-host disease (GvHD), or\r\n* Receiving immunosuppressive therapy as treatment for GvHD within the last 7 daysXx_NEWLINE_xXAt least 6 weeks from myeloablative therapy and autologous stem cell transplant (timed from stem cell infusion); patients who received stem cell infusion following non-myelo-ablative therapy are eligible once they meet all other eligibility requirements; patient must NOT have received a prior allogeneic hematopoietic stem cell transplantXx_NEWLINE_xXTREATMENT: Diagnosis of myeloma after receiving at least one treatment regimen; if patient has received an autologous or syngeneic stem cell transplant (SCT) they must be > 90 days post-transplant (Group A) OR\r\nfollowing autologous or syngeneic SCT (as adjuvant therapy) and < 90 days post-transplant (Group B)Xx_NEWLINE_xXPrior myeloablative or non-myeloablative allogeneic hematopoietic stem cell transplant using either bone marrow or peripheral blood stem cells or single or double cord blood within 24 months.Xx_NEWLINE_xXDiagnosis of a hematological malignancy requiring an allogeneic stem cell transplant consistent with the standard of careXx_NEWLINE_xXPatient with MDS who relapse after allogeneic stem cell transplant are eligible if they received standard dose decitabine or 5-azacytidine prior to or after stem cell transplantXx_NEWLINE_xXIf patient has undergone prior allogeneic stem cell transplant, they must be greater than 100 days post transplant and have =< grade 2 graft-versus-host diseaseXx_NEWLINE_xXPrior myeloablative or non-myeloablative autologous or allogeneic hematopoietic stem cell transplant using the marrow, peripheral blood stem cells or single or double umbilical cord bloodXx_NEWLINE_xXPatients who have received a prior allogeneic hematopoietic stem cell transplant (HSCT) and who have either rejected their grafts or who have become tolerant of their grafts with no active GVHD requiring immunosuppressive therapyXx_NEWLINE_xXPatients are eligible 12 weeks after autologous stem cell transplantXx_NEWLINE_xXIf a research participant has undergone prior allogeneic stem cell transplant, he/she must be off all immunosuppressants for graft versus host disease (GVHD) for at least 2 weeks before undergoing leukapheresis\r\n* Note: the above is not applicable if the research participant's done is undergoing leukapheresisXx_NEWLINE_xXIf a research participant has undergone prior allogeneic stem cell transplant (alloSCT), and has documented =< grade 2 graft versus host disease (GVHD) but the donor is undergoing leukapheresis, the research participant may be considered eligible for enrollment (at the discretion of the study principal investigator [PI]) provided that immunosupressants can be tapered off completely prior to lymphodepletionXx_NEWLINE_xXIf research participant is undergoing leukapheresis and the research participant has undergone prior alloSCT, two months must have elapsed since allogeneic stem cell transplant to undergo PBMC collection for T cell manufacturingXx_NEWLINE_xXStem Cell Transplant or Rescue: No evidence of active graft vs. host disease and ? 2 months must have elapsed since transplant.Xx_NEWLINE_xXPrior stem cell or bone marrow transplantXx_NEWLINE_xXPatients ineligible to receive full myeloablative conditioning regimen for allogeneic hematopoietic progenitor cell transplant due to age or comorbiditiesXx_NEWLINE_xXAllogeneic or autologous transplant for AML with infusion of stem cells within 90 days of study entry or on active immunosuppressive therapy for (GVHD) within 2 weeks before study entryXx_NEWLINE_xXPrior myeloablative or non-myeloablative allogeneic hematopoietic stem cell transplant using either bone marrow or peripheral blood stem cells or single or double cord blood within 18 monthsXx_NEWLINE_xXPrior autologous or allogeneic hematopoietic stem cellXx_NEWLINE_xXPrior allogeneic bone marrow/peripheral blood stem cell transplantXx_NEWLINE_xXPatients must not have a prior autologous, syngeneic or allogeneic hematopoietic stem cell transplantXx_NEWLINE_xXMajor anticipated illness or organ failure incompatible with survival from peripheral blood stem cell (PBSC) transplantXx_NEWLINE_xXSubjects with CD19+ B cell lymphomas with no available curative treatment options (such as autologous or allogeneic stem cell transplant [SCT]) who have a limited prognosis (several months to < 2 year survival) with currently available therapiesXx_NEWLINE_xXAutologous hematologic stem cell transplant within 3 months of study entry or Allogeneic hematologic stem cell transplant within 12 monthsXx_NEWLINE_xXPreceding allogeneic hematopoietic stem cell transplant (HSCT)Xx_NEWLINE_xXPatients must have relapsed after first line chemotherapy; may have relapsed after autologous or allogeneic stem cell transplant, or have primary refractory disease; no upper limit for number of prior therapies; if status post allogeneic stem cell transplant, no active graft versus host diseaseXx_NEWLINE_xXRANDOMIZED PHASE II (ARMS K AND L): Patients must have relapsed after first line chemotherapy; may have relapsed after autologous stem cell transplant, or have primary refractory disease; no upper limit for number of prior therapies; patient must not have received a prior allogeneic stem cell transplantXx_NEWLINE_xXPatients may have had a prior stem cell transplant (autologous or allogeneic), however they may not have active graft-vs-host disease (GvHD), nor be on any immunosuppressionXx_NEWLINE_xXPatients must be medically ineligible for allogeneic stem cell transplant (alloSCTx) or not have a known fully HLA matched sibling for planned sibling transplantXx_NEWLINE_xXPrior autologous stem-cell transplant (SCT) in the prior 3 monthsXx_NEWLINE_xXA prior autologous transplant within 3 months of study entry or allogeneic stem cell transplantXx_NEWLINE_xXPatients with the diagnosis of aplastic anemia who are either previously treated or untreated are eligible if they are not currently candidates for an allogeneic stem cell transplantXx_NEWLINE_xXNo active graft versus host disease (GVHD): patients with a history of stem cell transplant are eligible but cannot have evidence of active GVHD as determined by the investigatorXx_NEWLINE_xXPatients that are eligible (including having available donor) and willing to receive an allogeneic stem cell transplant within 4 weeksXx_NEWLINE_xXHistory of relapsed or refractory CD19+ malignancies (e.g. non Hodgkin lymphoma) who have failed prior treatment and require autologous hematopoietic stem cell transplant; evidence of disease not required (cohort 2)Xx_NEWLINE_xXReceived a hematopoietic stem cell transplant within the previous 2 monthsXx_NEWLINE_xX>= 3 months prior to registration for autologous bone marrow/stem cell transplantXx_NEWLINE_xXPatient must have not received any prior high dose chemotherapy and autologous stem cell transplantXx_NEWLINE_xXINCLUSION CRITERIA FOR STEM CELL TRANSPLANT WITH CONDITIONING (COHORT 1):Xx_NEWLINE_xXEXCLUSION CRITERIA FOR STEM CELL TRANSPLANT WITH CONDITIONING (COHORT 1):Xx_NEWLINE_xXPatients should meet one of the following diagnosis:\r\n* Patients with primary progressive disease on induction therapy with new targeted therapies\r\n* Relapsed/refractory disease on new targeted therapies, i.e. thalidomide, lenalidomide, bortezomib, or other new novel agents such as carfilzomib, pomalidomide\r\n* Patients with relapsed multiple myeloma following previous autologous stem cell transplant\r\n* Plasma cell leukemia at diagnosis\r\n* High-risk patients with presence of chromosome 17p deletion (> 60%) in the bone marrow by fluorescence in situ hybridization (FISH); patients are not required to have prior autologous stem cell transplantXx_NEWLINE_xXStem cells: patients must have an autologous hematopoietic stem cell product cryopreserved and available for re-infusion after 131I-8H9 treatment; the minimum dose for hematopoietic stem cells is 2 x 10^6 cluster of differentiation (CD)34+ cells/kgXx_NEWLINE_xXDONOR: Donors >= 18 years of age must be the same individual whose cells were used as the source for the patient’s original stem cell transplantXx_NEWLINE_xXPatients with stored autologous stem cells will be allowedXx_NEWLINE_xXStem cells from an identical donor could be used for autologous hematopoietic cell transplant (HCT)Xx_NEWLINE_xXPatients who have had a previous autologous or allogeneic stem cell transplant in the previous 12 monthsXx_NEWLINE_xXImmunoablative or myeloablative stem cell transplant (SCT): >= 6 months must have elapsed from prior autologous transplant; subjects must not have graft versus host disease post autologous transplantXx_NEWLINE_xXNo subjects who have received an allogeneic hematopoietic stem cell transplant are eligibleXx_NEWLINE_xXTwo prior stem cell transplants of any kindXx_NEWLINE_xXOne prior autologous stem cell transplant within the preceding 12 monthsXx_NEWLINE_xXOne prior allogeneic stem cell transplant within the preceding 24 monthsXx_NEWLINE_xXDONOR: donor selection will follow the Children’s Memorial Hospital Stem Cell Transplant Program policy VII-B entitled Allogeneic Donor Identification, Evaluation, Education, Consent and Management in the Stem Cell Transplant Standard Operating ManualXx_NEWLINE_xXStem cell sourceXx_NEWLINE_xXStem cells: patients must have an autologous hematopoietic stem cell product cryopreserved and available for re-infusion after MIBG treatment; the minimum dose for peripheral blood stem cells is 2 x 10^6 CD34+ cells/kgXx_NEWLINE_xXINCLUSION CRITERIA FOR CCT: patients must have an autologous hematopoietic stem cell product cryopreserved and available for re-infusion after MIBG treatment; the minimum dose for peripheral blood stem cells is 2 x 10^6 CD34+ cells/kgXx_NEWLINE_xXAllogeneic (non-autologous) bone marrow or stem cell transplant, or any stem cell infusion including donor lymphocyte infusion or boost infusion: ?84 days after infusion and no evidence of graft versus host disease (GVHD)Xx_NEWLINE_xXAutologous stem cell infusion including boost infusion: ?42 daysXx_NEWLINE_xXPatients with prior stem cell transplants.Xx_NEWLINE_xXPatients must have received at least 3 prior lines of therapy (Note: Induction therapy and stem cell transplant ± maintenance will be considered as one line).Xx_NEWLINE_xXHas allogenic haemopoietic stem cell (HSC) transplant.Xx_NEWLINE_xXMust be transplant ineligible as determined by their physician, or if transplant eligible, not expect to undergo transplant for at least 24 months after study enrollment. • Stem cell harvest and mobilization regimen is acceptable if clinically indicated, but must first be confirmed by the Takeda Medical Monitor.Xx_NEWLINE_xXHistory of, or scheduled, hematopoietic stem cell transplant within 24 weeks of ScreeningXx_NEWLINE_xXPrior bone marrow or stem cell transplant.Xx_NEWLINE_xXPrevious allogeneic stem cell transplant within 6 months prior to enrolment, active graft vs host disease (GVHD), or requiring transplant-related immunosuppressionXx_NEWLINE_xXPatients who received an autologous stem cell transplant must be ? 3 months post-transplant and all associated toxicities must have resolved to ? CTCAE Grade 1.Xx_NEWLINE_xXPatient had an allogeneic stem cell transplant within 6 months before first dose of PRLX 93936 or has evidence of graft versus host disease.Xx_NEWLINE_xXHodgkin's disease (HD): induction failures, second or third complete remission, or relapse (including relapse post autologous hematopoietic stem cell transplant)Xx_NEWLINE_xXPrior allogeneic stem cell transplant.Xx_NEWLINE_xXPatients who have received autologous stem cell transplant (ASCT) ? 8 weeks prior to the first dose of study drug or no adequate count recoveryXx_NEWLINE_xXSubjects must be deemed ineligible for both high-dose chemotherapy and hematopoietic stem cell transplant (based on age, performance status and/or comorbidities) while also having adequate organ function for CAR T cell treatment.Xx_NEWLINE_xXPrior hematopoietic stem cell transplantXx_NEWLINE_xXHave undergone stem cell transplant (SCT), or are considered transplant ineligible.Xx_NEWLINE_xXEvidence of ongoing graft-versus-host disease (GvHD) if prior stem cell transplant (SCT).Xx_NEWLINE_xXPrior allogeneic stem cell transplant with day 0 < 12 months prior and/or with chronic graft versus host disease (GVHD) requiring current use of immunosuppression; patients with prior allogeneic stem cell transplant with day 0 > 12 months prior who do not require immunosuppression for GVHD will be eligibleXx_NEWLINE_xXPrior allogeneic stem cell transplant within 6 months of study drug administration and no requirement for graft versus host therapy.Xx_NEWLINE_xXPreviously received allogeneic stem cell transplant and one or more of the following:Xx_NEWLINE_xXAdequate organ function for high dose chemotherapy and autologous stem cell transplant (as per institution standard operating procedure [SOP])Xx_NEWLINE_xXPatients who have received prior allogeneic stem cell transplantXx_NEWLINE_xXMeets standard eligibility requirements for high dose chemotherapy with autologous stem cell rescue (COHORT 1) or allogeneic hematopoietic stem cell transplant (COHORT 2) and has signed consent for those proceduresXx_NEWLINE_xXPatients undergoing haploidentical allogeneic hematopoietic stem cell transplants are not eligible; patients undergoing < 10/10 HLA allele matched allogeneic transplant are not eligibleXx_NEWLINE_xXPatients are eligible 12 weeks after myeloablative therapy with autologous stem cell transplant (timed from start of vorinostat); patients must meet adequate bone marrow function definition post-myeloablative therapy; patients who received stem cell reinfusion following non-myeloablative therapy are eligible once they meet peripheral blood count criteriaXx_NEWLINE_xXPatients status post-allogeneic stem cell transplant are not eligibleXx_NEWLINE_xXAvailability of autologous peripheral blood stem cell graft, containing at least 6.0 x 10^6 CD34+ cells/kgXx_NEWLINE_xXHistory of allogeneic organ or stem cell transplantXx_NEWLINE_xXStem cell transplant recipients must have no evidence of active graft-versus-host disease and should not be receiving treatment for itXx_NEWLINE_xXAllogeneic organ or stem cell transplantXx_NEWLINE_xXThe subject must be a recipient of hematopoietic stem cell or solid organ transplant.Xx_NEWLINE_xXIneligible for allogeneic stem cell transplantXx_NEWLINE_xXAll patients with relapsed/refractory lymphoma must have received or be ineligible for autologous stem cell transplant or be ineligible for allogeneic stem cell transplant\r\n* NOTE: Patients must not have had a prior allogeneic stem cell transplantXx_NEWLINE_xXPatients are not eligible who have had a prior allogeneic stem cell transplant\r\n* NOTE: Autologous stem cell transplant is acceptableXx_NEWLINE_xXPrior allogeneic stem cell or solid organ transplantXx_NEWLINE_xXPrior hematopoietic stem cell transplant within 6 months of enrollment. If the subject had an allogenic transplant there must be no apparent signs of graft versus host disease and subjects must have discontinued all immunosuppressive therapies for at least 4 weeksXx_NEWLINE_xXPatients who are primarily eligible for autologous stem cell transplantXx_NEWLINE_xXHas received high-dose melphalan and autologous stem cell transplant (HDM-ASCT) within 12 weeks before the first infusion or are planning for HDM-ASCTXx_NEWLINE_xXAll previous chemotherapy or radiation must be completed at least 3 weeks prior to study entry; immunologic therapy must be completed at least 1 week prior to study entry; patients with prior stem cell transplant must be greater than 365 days post-transplantXx_NEWLINE_xXStem cell transplant (SCT): no evidence of active graft vs. host disease for at least 4 weeks; for allogeneic SCT patients, >= 3 months must have elapsed since transplant\r\n* Must have received no more than 1 prior autologous or allogeneic stem cell transplant.\r\n* Patients must be off all systemic immunosuppressive therapy for at least 2 weeks, excluding hydrocortisone for physiologic cortisol replacementXx_NEWLINE_xXIs within the first 100 days of having undergone an allogeneic stem cell transplant; otherwise, patients who have received an allogeneic stem cell transplant are allowed as long as they have no evidence of active graft versus host disease (GVHD) or are on immunosuppressive therapyXx_NEWLINE_xXUndergone an organ transplant(s) including allogeneic stem cell or bone marrow transplantsXx_NEWLINE_xXPrevious bone marrow or stem cell transplantXx_NEWLINE_xXHematopoietic cell transplant-co-morbidity Index greater than 2Xx_NEWLINE_xXPatient must be scheduled to receive high dose chemotherapy and autologous stem cell transplant for multiple myelomaXx_NEWLINE_xXPatients who have previously undergone autologous stem cell transplant are eligible for this study provided more than 6 months have elapsed from the prior transplantXx_NEWLINE_xXPatients must have a minimum stem cell dose of 4x10^6 CD34+ MNC/kg stored for autologous stem cell rescueXx_NEWLINE_xXStem Cell Transplant (SCT): \r\n* Patients are eligible 6 weeks after date of autologous stem cell infusion following myeloablative therapy (timed from first day of protocol therapy)\r\n* Patients are not eligible post allogeneic stem cell transplant\r\n* Patients who have received an autologous stem cell infusion to support non-myeloablative therapy (such as 131 iodine [I]-MIBG) are eligible at any time as long as they meet the other criteria for eligibilityXx_NEWLINE_xXDisease must be refractory or relapsed after >= 3 prior regimens (induction therapy and stem cell transplant +/- maintenance will be considered as one regimen)Xx_NEWLINE_xXAdequate autologous stem cell collection, defined as an unmanipulated, cryopreserved, peripheral blood stem cell collection containing at least 2 x 10^6 cluster of differentiation (CD)34+ cells/kg based on patient body weightXx_NEWLINE_xXPrior stem cell transplant (autologous or allogeneic)Xx_NEWLINE_xXHave measurable or evaluable disease, as defined in 2007 Revised Response Criteria for Malignant Lymphoma; HL patients must not be currently eligible for autologous stem cell transplantXx_NEWLINE_xXAt least one prior therapy for CLL/SLL; prior autologous or allogeneic stem cell transplant is allowed; patients may not be on chronic immunosuppressive therapy for graft-versus-host disease (GVHD); patients who are on only oral steroids must be on an oral dose of 10mg or less of prednisone (or equivalent) dailyXx_NEWLINE_xXStem cell transplant or rescue: >= 2 months must have elapsed since the time of transplant; patients with active graft-vs-host disease (GVHD) are eligible if the disease is well controlled on GVHD medications and they are clinically stableXx_NEWLINE_xXPatients with a history of allogeneic stem cell transplant for MDS or any other antecedent hematologic disorder are not eligibleXx_NEWLINE_xXHas no other hematopoietic stem cell transplant of any type prior to the current planned autologous hematopoietic cell transplantXx_NEWLINE_xXHas received any type of hematopoietic cell transplantXx_NEWLINE_xXEvidence of multiple myeloma disease progression (as defined by IMWG) any time prior to autologous (auto)-hematopoietic stem cell transplant (HSCT)Xx_NEWLINE_xXStem cell infusion without TBI: no evidence of active graft vs. host disease and at least 84 days must have elapsed after transplant or stem cell infusionXx_NEWLINE_xXPrior allogeneic or autologous hematopoietic stem cell transplant in the last 6 monthsXx_NEWLINE_xXPrior allogeneic bone marrow or stem cell transplantXx_NEWLINE_xXPrior autologous bone marrow or stem cell transplant within 1 year of enrollmentXx_NEWLINE_xXPatients that have received a prior autologous or allogeneic stem cell transplantXx_NEWLINE_xXPrior autologous or allogeneic stem cell transplantXx_NEWLINE_xXBone marrow/stem cell transplant or infusion without TBI:\r\n* Part A1 or Part C: No evidence of active graft vs host disease and >= 3 months must have elapsed since stem cell transplant or infusion\r\n* Part A2, Part A3, or Part B: No evidence of active graft vs host disease and >= 6 weeks must have elapsed since stem cell transplant or infusionXx_NEWLINE_xXPrior allogeneic bone marrow or stem cell transplantXx_NEWLINE_xXPrior autologous bone marrow or stem cell transplant or prior radiation therapy (RT) > 20 Gy to a critical organ within 1 year of enrollmentXx_NEWLINE_xXSubject is refractory to or relapsed after first-line AML therapy (with or without hematopoietic stem cell transplant (HSCT)).Xx_NEWLINE_xXAutologous bone marrow transplant or stem cell rescue within four months of start of study drugXx_NEWLINE_xXConsidered eligible for high-dose chemotherapy followed by autologous stem cell transplant (ASCT)Xx_NEWLINE_xXHistory of autologous or allogeneic stem cell transplantXx_NEWLINE_xXPrior allogeneic stem cell or solid organ transplantXx_NEWLINE_xXPrior history of hematopoietic stem cell transplantXx_NEWLINE_xXPrior allogeneic stem cell transplantXx_NEWLINE_xXPrior allogeneic hematopoietic stem cell transplant.Xx_NEWLINE_xXUnless approved by the medical monitor, may not have received an allogeneic hematopoietic stem cell transplant within 6 months before treatment, or have active graft-versus-host-disease following allogeneic transplantXx_NEWLINE_xXUnless approved by the medical monitor, may not have received autologous hematopoietic stem cell transplant within 3 months before treatmentXx_NEWLINE_xXThey have had an allogeneic stem cell transplant (received stem cell from someone else)Xx_NEWLINE_xXPatients status post allogeneic stem cell transplant.Xx_NEWLINE_xXOnly non transplant candidates or those who opt to forgo autologous stem cell transplant (ASCT) during first line therapy are eligibleXx_NEWLINE_xXPrevious allogeneic stem cell transplant.Xx_NEWLINE_xXHas received autologous stem cell transplant (auto-SCT) within 12 weeks before the first infusion or is planning for or is eligible for auto-SCTXx_NEWLINE_xXPrior allogeneic stem cell or autologous transplant.Xx_NEWLINE_xXIf a participant has received a transplant as his/her first-line therapy, he/she must be at least 3 months post transplantation and recovered from the side effects of the stem cell transplant.Xx_NEWLINE_xXReceipt of an allogeneic bone marrow or allogeneic stem cell transplantXx_NEWLINE_xXPrior allogeneic or autologous stem cell transplantXx_NEWLINE_xXEligible for allogenic or autologous stem cell transplantXx_NEWLINE_xXPrior hematopoietic stem cell transplant.Xx_NEWLINE_xXConsidered eligible for hematopoietic stem cell transplant (allogeneic or autologous) at the time of signing the ICF.Xx_NEWLINE_xXPrior allogeneic stem cell transplant within one year or active graft vs. host disease.Xx_NEWLINE_xXHas received prior allogeneic transplants or who are planned to undergo umbilical cord blood transplant, receive ex vivo T-cell-depleted hematopoietic stem cells (HSCs), received any in vivo T-cell depleting antibodies, or non-myeloablative conditioning.Xx_NEWLINE_xXPrior autologous stem cell transplant within 12 weeksXx_NEWLINE_xXAutologous stem cell transplant less than 90 days prior to study day 1Xx_NEWLINE_xXTreatment with high-dose chemotherapy and hematopoietic stem-cell rescue within 3 months prior to initiation of study drugXx_NEWLINE_xXCompletion of autologous stem cell transplant (SCT) within 100 days prior study startXx_NEWLINE_xXSubjects must have histologically documented relapsed or refractory disease, with a diagnosis of one of the following lymphoid malignancies: diffuse large B-cell lymphoma, peripheral T-cell lymphoma (any subtype); subjects must have received at least one prior systemic chemotherapy and must have either received an autologous stem cell transplant, refused or been deemed ineligible for an autologous stem cell transplantXx_NEWLINE_xXAllogeneic stem cell transplant within the last 6 months, or active-graft-versus-host disease following allogeneic transplant, or subjects currently on immunosuppressive therapy following allogeneic transplantXx_NEWLINE_xXRelapsed or refractory DLBCL, which has been histologically documented, defined as having received at least 2 but no more than 5 prior treatment regimens and ineligible for high-dose chemotherapy supported by autologous stem cell transplant.Xx_NEWLINE_xXAllogeneic stem cell transplant within the last 6 months, or active graft versus host disease following allogeneic transplant, or autologous stem cell transplant within the last 3 months.Xx_NEWLINE_xXAutologous hematologic stem cell transplant within 3 months of study entry. Prior Allogeneic hematologic stem cell transplant is excludedXx_NEWLINE_xXPatients who received an allogeneic bone marrow or allogeneic peripheral blood stem cell transplant less than 12 months prior to initiation of studyXx_NEWLINE_xXMust have received prior high-dose conditioning chemotherapy followed by autologous stem cell transplant (ASCT) as a part of salvage therapy for cHL (cohort A, B & C - enrolment closed)Xx_NEWLINE_xXPatients may have had a prior autologous stem cell transplant; no prior history of allogeneic stem cell transplantXx_NEWLINE_xXPost-autologous stem cell transplant (ASCT) or not a candidate for ASCT; prior allogeneic stem cell transplant is allowed if patient is off all immunosuppressives and has no evidence of active graft-versus-host disease (GVHD)Xx_NEWLINE_xXPrior peripheral stem cell transplant within 12 weeks of patient registrationXx_NEWLINE_xXNo evidence of active graft vs host and <3mo since Stem Cell TransplantXx_NEWLINE_xXBack-up stem cell sourceXx_NEWLINE_xXPatients with AML\r\n* Patients with therapy-related myeloid neoplasms are allowed\r\n* Patients with AML that has evolved from an antecedent hematologic disorder are allowed\r\n* Patients will be eligible regardless of their ultimate plans or candidacy for allogeneic stem cell transplantXx_NEWLINE_xXLess than 100 days for subjects receiving autologous hematologic stem cell transplant (HSCT); or 6 months for subjects receiving allogenic HSCT or either transplant type, if otherwise not fully recovered from HSCT related toxicity.Xx_NEWLINE_xXHistory of hematopoietic stem cell transplantXx_NEWLINE_xXIf participant had prior allogeneic stem cell transplant (SCT), participant has evidence of ongoing graft-versus-host disease (GvHD).Xx_NEWLINE_xXhave MCL that relapsed after or is refractory to (a) first-line combination chemotherapy with or without stem cell transplant and (b) at least 1 other locally available therapyXx_NEWLINE_xXPrior bone marrow or stem cell transplantXx_NEWLINE_xXParticipant has previously received an allogenic stem cell transplant; or participant has received autologous stem cell transplantation (ASCT) within 12 weeks before Cycle 1 Day 1Xx_NEWLINE_xXPrior allogeneic hematopoietic stem-cell transplant for participants with DLBCL, FL, MCL, and CLL only. Prior allogenic hematopoietic stem-cell transplant is permitted for participants with ALLXx_NEWLINE_xXCompletion of autologous stem cell transplant within 100 days prior to Cycle 1, Day 1Xx_NEWLINE_xXPrior allogeneic stem cell transplantXx_NEWLINE_xXPatients must have failed autologous stem cell transplant or at least 2 prior cytotoxic regimens for Hodgkin lymphoma; patients who have failed only 1 prior cytotoxic regimen for Hodgkin lymphoma are permitted to enroll as long as they are not eligible for autologous stem cell transplantXx_NEWLINE_xXPatients with diffuse large B cell lymphoma must have received at least two prior therapies and have received, declined or be ineligible for autologous or allogeneic stem cell transplantXx_NEWLINE_xXSubjects who have previously received an autologous stem cell transplant are allowed if a minimum of 3 months has elapsed from the time of transplant and the subject has recovered from transplant-associated toxicities prior to the first dose of GSK2879552.Xx_NEWLINE_xXSubjects with a history of allogeneic stem cell transplant are eligible for study participation provided the following eligibility criteria are met: transplant was >60 days prior to study enrolment; subject has not taken immunosuppressive medications for at least 1 month; no signs or symptoms of graft versus host disease other than Grade 1 skin involvement; no active infection.Xx_NEWLINE_xXReceived allogeneic hematopoietic stem cell transplant within the last 6 months, or has active graft versus host disease (GVHD) following allogeneic transplant, or currently receiving immunosuppressive therapy following allogeneic transplantXx_NEWLINE_xXReceived autologous hematopoietic stem cell transplant within the last 3 monthsXx_NEWLINE_xXPrior autologous or allogeneic bone marrow or stem cell transplantXx_NEWLINE_xXPatients are eligible >= 6 weeks after autologous stem cell transplants or stem cell infusions as long as hematologic and other eligibility criteria have been metXx_NEWLINE_xXParticipants received an allogeneic stem cell transplantXx_NEWLINE_xXPatients must have history of symptomatic myeloma requiring treatment and meet one of the following requirements:\r\n* Have at least 1 high risk feature at diagnosis (including deletion 13 or hypodiploidy by conventional cytogenetics, t(4;14), t(14;16) or deletion 17 by fluorescence in situ hybridization [FISH], beta 2 microglobulin > 3.5, lactate dehydrogenase [LDH] greater than 1.5 x upper limit of normal [ULN], history of plasma cell leukemia) (prior to chemotherapy); OR\r\n* Have progressive disease on primary therapy with or without prior autologous stem cell transplant; OR \r\n* Have persistent or progressive disease following autologous transplant; it is acceptable for these patients to have a second transplant for disease reductionXx_NEWLINE_xXRefractory disease (defined as persistence of evaluable disease after therapy) or relapsed disease following at least one prior treatment regimen that should include autologous stem cell transplant unless a patient was not eligible or refused prior transplantXx_NEWLINE_xXSubjects may be enrolled who relapse after autologous stem cell transplant if they are at least 3 months after transplant, and after allogeneic transplant if they are at least 6 months post transplant.Xx_NEWLINE_xXPrior allogeneic stem cell or solid organ transplantXx_NEWLINE_xXRelapsed or refractory DLBCL, defined as having received at least 1 but no more than 3 prior treatment regimens and ineligible for high-dose chemotherapy/autologous stem cell transplant.Xx_NEWLINE_xXAllogeneic stem cell transplant within the previous 6 months, or active graft versus host disease following allogeneic transplant.Xx_NEWLINE_xXPrior autologous hematopoietic stem cell transplant ? 3 months.Xx_NEWLINE_xXPrior allogeneic hematopoietic stem cell transplant (HSCT) with either standard or reduced intensity conditioning ? 6 months.Xx_NEWLINE_xXRelapsed or refractory disease after allogeneic transplant provided subject is at least 100 days from stem cell transplant at the time of enrollmentXx_NEWLINE_xXPlans to undergo a stem cell transplant prior to progression of disease on this study (these participants should not be enrolled to reduce disease burden prior to transplant)Xx_NEWLINE_xXPrior allogeneic stem cell transplantXx_NEWLINE_xXPatients who have had allogeneic hematopoietic stem cell transplant (HSCT) are not eligible if they meet any of the following: \r\n* transplant is within 2 months from cycle 1, day 1 (C1D1) \r\n* Has clinically significant graft-versus-host disease requiring treatment\r\n* Has >= grade 3 persistent non-hematological toxicity related to the transplantXx_NEWLINE_xXPatient has histologically confirmed diagnosis of R/R mantle cell lymphoma, follicular lymphoma or diffuse large B cell lymphoma\r\n* Diffuse large B cell lymphoma patients has received at least 1 prior regimen and received, declined, or is ineligible for autologous or allogeneic stem cell transplant\r\n* Follicular lymphoma patients have received at least 2 lines of therapy\r\n* Mantle cell lymphoma patients has received at least 1 line of therapy\r\n* Allogeneic stem cell transplant recipients be greater than 6 months post transplant, not on immunosuppression for prevention of graft versus host disease for > 3 months and without active graft versus host disease are eligible\r\n* Autologous stem cell transplant recipients must have adequate bone marrow recovery and transfusion independent\r\n* Transformed histologies are permittedXx_NEWLINE_xXPatients with previous allogeneic stem cell transplant (SCT) within 6 months or with active acute or chronic graft-versus host disease are excluded; patients must be off immunosuppression for GVHD for at least 60 days before cycle 1 day 1Xx_NEWLINE_xXPatients undergoing allogeneic stem cell transplant using a peripheral blood stem cell sourceXx_NEWLINE_xXParticipant may have failed to achieve a response to, progressed after, or be ineligible for autologous stem cell transplant (auto-SCT)Xx_NEWLINE_xXPrior allogeneic stem cell transplant (SCT) within 16 weeks or autologous SCT within 8 weeks of initiation of therapy (patients that require immunosuppressive therapy are not eligible within 60 days of therapy)Xx_NEWLINE_xXPatient must be:\r\n* >= 6 months since allogeneic bone marrow transplant prior to enrollment\r\n* >= 3 months since autologous bone marrow/stem cell prior to enrollment\r\n* >= 3 months since stem cell transplant or rescue without TBI with no graft vs. host disease prior to enrollment\r\n* No graft versus host diseaseXx_NEWLINE_xXPreviously received an organ or allogeneic progenitor/stem cell transplant.Xx_NEWLINE_xXPrior allogeneic stem cell or solid organ transplantXx_NEWLINE_xXNote: prior autologous stem cell transplant as well as radiation to the CNS is NOT an exclusion criterion; prior allogenic stem cell transplant IS an exclusion criterionXx_NEWLINE_xXPatients who have received allogenic stem cell transplantsXx_NEWLINE_xXAutologous hematologic stem cell transplant within 3 months of study entry. Prior Allogeneic hematologic stem cell transplant is excludedXx_NEWLINE_xXParticipant is a candidate for a bone marrow or stem cell transplant within 12 weeks after study enrollment.Xx_NEWLINE_xXPrior allogeneic stem cell transplant (SCT) within 16 weeks or autologous SCT within 8 weeks of initiation of therapy; (patients that require immunosuppressive therapy are not eligible within 60 days of therapy)Xx_NEWLINE_xXAutologous hematologic stem cell transplant within 3 months of study entry; allogeneic hematologic stem cell transplant within 12 months; post allogeneic (allo) patients must not have active graft versus-host disease and be off all immune suppression (other than steroids, as above)Xx_NEWLINE_xXOnly patients who received prior systemic therapy with relapsed/refractory organ disease are eligible, unless they have declined or are not eligible for high-dose melphalan and autologous hematopoietic stem cell transplant (HSCT) or any other standard therapy that has been known to be life-prolonging or life-savingXx_NEWLINE_xXSubjects can be enrolled and treated under this protocol regardless of their CLL treatment history or number of previous treatments; in addition, subjects with history of allogeneic stem cell transplant can be enrolled and treated unless they have active manifestations of graft versus (vs.) host disease (GVHD) or chronic illness or infections that will prevent them from completing the studyXx_NEWLINE_xXRelapsed or refractory after an autologous stem cell transplant (ASCT) or at least two prior multi-agent chemotherapy regimens in patients not candidates for ASCTXx_NEWLINE_xXAutologous hematologic stem cell transplant within 3 months of study entry. Patients who had prior Allogeneic hematologic stem cell transplant are excludedXx_NEWLINE_xXSubject has undergone an allogeneic stem cell transplant within the past yearXx_NEWLINE_xXPrior allogeneic stem cell or solid organ transplantXx_NEWLINE_xXHave received an autologous or allogeneic stem-cell transplantXx_NEWLINE_xXImmunomodulatory therapy such as immunomodulatory drugs (Imids) or stem cell transplant within 28 days prior to the first day of treatmentXx_NEWLINE_xXHas received autologous stem cell transplantation within 12 weeks before the date of randomization, or previously received an allogenic stem cell transplant (regardless of timing), or planning to undergo a stem cell transplant prior to progression of diseaseXx_NEWLINE_xXAny antitumor systemic cytotoxic therapies within 28 days prior to enrollment (6 weeks for nitrosoureas or mitomycin-C); prior high-dose chemotherapy with bone marrow or stem cell transplant is excludedXx_NEWLINE_xXPrior allogeneic stem cell transplantXx_NEWLINE_xXPrior autologous stem cell transplant ?12 weeks prior to first dose of study drugXx_NEWLINE_xXPrior allogeneic stem cell transplant (SCT), chest radiation ? 24 weeks from study drug, ?1000 mg of Carmustine Bis-chloroethylnitrosourea (BCNU) as part of pre-transplant conditioning regimen, prior treatment with drug targeting T-cell costimulation or immune checkpoint pathwaysXx_NEWLINE_xXPost autologous stem cell transplant bone marrow biopsy core that is consistent with morphologic remissionXx_NEWLINE_xXMust have received induction and consolidation chemotherapy, and autologous stem cell transplant for AMLXx_NEWLINE_xXPatient received another investigational agent after post autologous stem cell transplantXx_NEWLINE_xXActive graft-versus-host disease (GVHD) following allogeneic stem cell transplant for non-AML condition (ex. MDS, MPN, lymphoid malignancy, aplastic anemia) requiring ongoing use of immunosuppressantsXx_NEWLINE_xXNo autologous or allogeneic stem cell transplant within 3 months prior to cycle 1 day 1Xx_NEWLINE_xXPatients who have previously undergone allogeneic hematopoietic stem cell transplant will be excluded from this studyXx_NEWLINE_xXAutologous stem cell transplant or rescue: No evidence of active graft versus (vs.) host disease and >= 4 weeks must have elapsedXx_NEWLINE_xXPatients within 1 year of allogeneic stem cell transplant, patients with active graft versus host disease (GVHD) or requiring immunosuppression are excludedXx_NEWLINE_xXUndergone an allogenic stem cell transplantXx_NEWLINE_xXPrior allogeneic transplant (prior autologous stem cell transplant >6 months prior to study entry is permitted)Xx_NEWLINE_xXPatients must have relapsed or refractory disease following frontline chemotherapy; no upper limit for the number of prior therapies; patients may have relapsed after prior autologous or allogeneic stem cell transplantXx_NEWLINE_xXMust not be a candidate for autologous stem cell transplant (ASCT), has declined the option of ASCT, or has relapsed after prior ASCTXx_NEWLINE_xXPrior solid organ transplantation or allogenic stem cell transplantation (ASCT). However, previous autologous BM transplant (ABMT) or autologous peripheral blood stem cell transplant (PBSCT) is permitted.Xx_NEWLINE_xXAllogeneic hematopoietic stem cell transplant within 100 days prior to leukapheresisXx_NEWLINE_xXPatients who have undergone autologous stem cell transplant more than 3 months prior are eligibleXx_NEWLINE_xXPatients who have undergone allogeneic stem cell transplant within 12 months, without active graft-versus-host-disease, and not on immunosuppression for prevention of graft-versus-host disease are eligibleXx_NEWLINE_xXStem cell infusions (with or without total body irradiation): Allogeneic (non-autologous) bone marrow or stem cell transplant, or any stem cell infusion including donor leukocytes infusion or boost infusion: ?84 days after infusion and no evidence of graft versus host disease; Autologous stem cell infusion including boost infusion: ?42 daysXx_NEWLINE_xXPatients must have received at least one prior therapy; prior autologous stem cell transplant is permitted; patients with diffuse large B-cell lymphoma who have not received high-dose therapy (HDT)/autologous stem cell transplant (ASCT) must be ineligible for HDT/ASCT; prior allogeneic stem cell transplant is not permitted; prior ibrutinib is not permittedXx_NEWLINE_xXPrior autologous stem cell transplant =< 12 weeks prior to registrationXx_NEWLINE_xXInclusion Criteria:\n\n        • Aged 18 years or older, with lymphoid malignancies of B-cell origin as follows:\n\n        *Indolent / aggressive B-cell (NHL) Non- Hodgkin's Lymphoma:\n\n        EXCLUDING: Burkitt lymphoma and precursor B-lymphoblastic leukemia/lymphoma\n\n        INCLUDING: any non-Hodgkin's B-cell malignancy such as CLL and rare non-Hodgkin's B-cell\n        subtypes such as Hairy Cell Leukemia, Waldenstrom macroglobulinemia, Mantle cell lymphoma,\n        transformed NHL histologies, etc.\n\n        *Hodgkin's lymphoma\n\n          -  Life expectancy of 12 weeks or longer.\n\n          -  Subject must have received ? 1 prior treatment regimen.\n\n          -  The subject must not be a candidate for potentially curative therapy, including stem\n             cell transplant.\n\n        Exclusion Criteria:\n\n          -  Received an investigational study drug within 28 days or 5 half-lives (whichever is\n             longer) prior to receiving the first dose of study drug.\n\n          -  Received any approved anticancer medications within 21 days or 5 half-lives (whichever\n             is longer) prior to receiving their first dose of study drug (42 days for\n             nitrosoureas) EXCEPT steroids at ? 10 mg prednisone daily (or equivalent).\n\n          -  Has any unresolved toxicity ? Grade 2 from previous anticancer therapy.\n\n          -  Has history of brain metastases or spinal cord compression, or lymphoma involving the\n             central nervous system.\n\n          -  Has an Eastern Cooperative Oncology Group (ECOG) performance status of ? 3.\n\n          -  Received allogeneic hematopoietic stem cell transplant within the last 6 months, or\n             has active graft versus host disease (GVHD) following allogeneic transplant, or is\n             currently receiving immunosuppressive therapy following allogeneic transplant.\n\n          -  Received autologous hematopoietic stem cell transplant within the last 3 months.\n\n          -  Laboratory parameters not within the protocol-defined range.\n\n          -  Current or recent history (<30 days prior to screening and/or <45 days prior to\n             dosing) of a clinically meaningful bacterial, fungal, parasitic or mycobacterial\n             infection.\n\n          -  Current clinically active viral infection.\n\n          -  Known history of infection with the human immunodeficiency virus (HIV).\n\n          -  History of active hepatitis or positive serology for hepatitis.Xx_NEWLINE_xXPrior history of allogeneic hematopoietic stem cell transplant (HSCT).Xx_NEWLINE_xXNewly diagnosed, symptomatic multiple myeloma patients for whom treatment is indicated per the NCCN guidelines, and for whom a hematopoietic stem cell transplant is not planned or scheduled during the study or are considered ineligible for hematopoietic stem cell transplant, with measurable diseaseXx_NEWLINE_xXPrevious participation in a stem cell study within last 30 daysXx_NEWLINE_xXPrior autologous or allogeneic bone marrow/peripheral blood stem cell transplantXx_NEWLINE_xXSubjects with a history of autologous or allogenic stem cell transplant must have adequate bone marrow independent of any growth factor support, and have recovered from any transplant related toxicity(s); and either greater than 100 days post-autologous transplant (prior to first dose of study drug) or greater than or equal to 6 months post-allogenic transplant (prior to first dose of study drug) and not have active graft-versus-host disease (i.e., requiring treatment).Xx_NEWLINE_xXAutologous hematologic stem cell transplant within 3 months of study entry or Allogeneic hematologic stem cell transplant within 12 months;Xx_NEWLINE_xXSubject has no available or declines curative treatment options such as allogeneic stem cell transplant (SCT) and has limited prognosis (< 2 years survival) with currently available therapiesXx_NEWLINE_xXRecovered (i.e., =< grade 1 toxicity) from the reversible effects of autologous stem cell transplantXx_NEWLINE_xXReceived at least one prior systemic therapy, which may include stem cell transplant, for AL amyloidosis;Xx_NEWLINE_xXRecipients of prior allogeneic hematopoietic stem cell transplant (HSCT) with active acute or chronic GVHDXx_NEWLINE_xXPatient must not have undergone a prior allogeneic stem cell transplantXx_NEWLINE_xXTwo prior stem cell transplants of any kindXx_NEWLINE_xXOne prior autologous stem cell transplant within the preceding 12 monthsXx_NEWLINE_xXOne prior allogeneic stem cell transplant within the preceding 24 monthsXx_NEWLINE_xXMyeloablative or non-myeloablative allogeneic hematopoietic cell transplantXx_NEWLINE_xXPatients with prior autologous or allogeneic stem cell transplant are eligible as long as they meet all other criteriaXx_NEWLINE_xXHigh-dose chemotherapy with stem-cell rescue: interval >= 3 months before study enrollmentXx_NEWLINE_xXPatients who have received a stem cell transplant in the past.Xx_NEWLINE_xXPatients who can receive an allogeneic stem cell transplant within 4 weeks.Xx_NEWLINE_xXPrior allogeneic hematopoietic stem cell transplantXx_NEWLINE_xXPrior autologous stem cell transplant within previous 3 monthsXx_NEWLINE_xXHave previously received an allogenic stem cell transplantXx_NEWLINE_xXHave received autologous stem cell transplant within 12 weeks before the first infusionXx_NEWLINE_xXPatients for whom the goal of therapy is tumor debulking prior to stem cell transplantXx_NEWLINE_xXReceived a hematopoietic stem cell transplantXx_NEWLINE_xXSubject progressed during or within 2 months of completion of their last planned course of salvage therapy with chemotherapy (with or without rituximab, may include autologous stem cell transplant).Xx_NEWLINE_xXNot a candidate for autologous stem cell transplant (ASCT) or declined option.Xx_NEWLINE_xXPrior allogeneic stem cell transplantXx_NEWLINE_xXPatients who underwent stem cell transplant (SCT) in first complete remission are eligible, as long as all of the following criteria are met:\r\n* At least 100 days have elapsed since stem cell infusion\r\n* At least 14 days off of all medications for graft-versus-host-disease (GVHD) prophylaxis or treatment\r\n* No evidence of acute GVHDXx_NEWLINE_xXIndividuals who have had a stem cell transplant and are still receiving treatment for GVHD or GVHD prophylaxis, or who have evidence of acute GVHD, or who are less than 100 days from stem cell infusionXx_NEWLINE_xXThe patient had a previous bone marrow or stem cell transplantXx_NEWLINE_xXPatients who meet previous criterion or have any of the following are eligible: \r\n* Less than partial response (PR) to salvage chemotherapy\r\n* Kinetic failure\r\n* Having received more than 3 lines of therapy\r\n* Failure to mobilize autologous stem cell\r\n* 10% or more marrow involvement\r\n* 6 months post autologous stem cell transplantXx_NEWLINE_xXA prior allogeneic stem cell transplantXx_NEWLINE_xXPrior allogeneic hematopoietic stem cell transplantXx_NEWLINE_xXBoth potentially autologous stem cell transplant (autoSCT) or allogeneic stem cell transplant (alloSCT) candidates and those who are not transplant candidates are eligible for the studyXx_NEWLINE_xXAutologous stem cell rescue within 12 weeks before study enrollment or those who underwent allogeneic stem cell transplant within one year of enrollmentXx_NEWLINE_xXHave received an autologous or allogeneic stem-cell transplant within 75 days of the initial dose of study drugXx_NEWLINE_xXA diagnosis of a hematologic malignancy for which stem cell transplant is standard of careXx_NEWLINE_xXPatients with prior autologous stem cell transplants will be included; patients with prior allogeneic stem cell transplants will be eligible for 2nd BMT if not previously transplanted with FLT on 11-c-0136Xx_NEWLINE_xXCLL subject has undergone an allogeneic or autologous stem cell transplant or NHL subject has undergone an allogeneic stem cell transplant or has been diagnosed with Post-Transplant Lymphoproliferative Disease, Burkitt's lymphoma, Burkitt-like lymphoma, or lymphoblastic lymphoma/leukemia.Xx_NEWLINE_xXNot eligible for high-dose chemotherapy and stem cell transplant.Xx_NEWLINE_xXUnderwent stem cell transplant <60 days prior to receiving first dose of ponatinibXx_NEWLINE_xXHave received at least 2 prior treatment, which may include stem cell transplant.Xx_NEWLINE_xXHad allogeneic stem cell transplant within last 6 months and on immunosuppressive therapy.Xx_NEWLINE_xXNo autologous stem cell transplant within 6 months prior to registration for protocol therapyXx_NEWLINE_xXAll previous therapy not associated with peripheral blood stem cell transplant, including radiation, hormonal therapy, and surgery, must have been discontinued 4 weeks prior to treatment in this studyXx_NEWLINE_xXAllogeneic stem cell transplant within the last 6 months, or autologous stem cell transplant within the last 3 months before the date of the first dose of study treatment.Xx_NEWLINE_xXPrevious allogeneic stem cell transplantXx_NEWLINE_xXPrevious autologous stem cell transplant, fludarabine therapy, or radioimmunotherapy in the past 12 monthsXx_NEWLINE_xXHistory of allogeneic bone marrow/stem cell transplantXx_NEWLINE_xXPrior allogeneic stem cell transplantXx_NEWLINE_xXPatients previously treated with allogeneic stem cell transplant (SCT) that is currently complicated by active graft versus host disease (GVHD) requiring T cell suppressive therapyXx_NEWLINE_xXStem cell transplant within 60 daysXx_NEWLINE_xXSubjects who have undergone stem cell transplant who are undergoing treatment or prophylaxis for Graft versus host diseaseXx_NEWLINE_xXNon-Hodgkin's lymphoma - induction failures, second or third complete remission, or relapse (including relapse post autologous hematopoietic stem cell transplant)Xx_NEWLINE_xXHodgkin's disease - induction failure, second or later complete remission, or relapse (including relapse post autologous hematopoietic stem cell transplant)Xx_NEWLINE_xXDONOR: Marrow will be the only allowed hematopoietic stem cell sourceXx_NEWLINE_xXHodgkin's disease (HD): induction failures, second or third complete remission, or relapse (including relapse post autologous hematopoietic stem cell transplant); orXx_NEWLINE_xXPrevious allogeneic stem cell transplantXx_NEWLINE_xXReceipt of allogenic or autologous stem cell transplantXx_NEWLINE_xXPrior autologous hematopoietic stem cell transplantXx_NEWLINE_xXPatients who have experienced their relapse after a hematopoietic stem cell transplant (HSCT) are eligible, provided all of the following are met: \r\n* No evidence of acute or chronic graft-versus-host disease (GVHD)\r\n* At least 14 days off all medications for GVHD\r\n* At least 60 days post-transplant at the time of enrollmentXx_NEWLINE_xXPatients who are candidates for allogeneic stem cell transplant at the time of enrollmentXx_NEWLINE_xXStem cell transplant within 3 monthsXx_NEWLINE_xXPatients status post-allogeneic stem cell transplant are not eligible.Xx_NEWLINE_xXPrior hematopoietic stem cell transplantXx_NEWLINE_xXHyperacute GvHD defined as onset of GvHD within the first 15 days following hematopoietic stem cell infusion.Xx_NEWLINE_xXCandidates for allogeneic stem cell transplant at the time of screening.Xx_NEWLINE_xXNot eligible for stem cell/bone marrow transplant or have refused stem cell/bone marrow transplant or have relapsed after autologous or allogeneic stem cell/bone marrow transplantXx_NEWLINE_xXHas had a prior stem cell or bone marrow transplantXx_NEWLINE_xXAny bone marrow relapse after allogeneic hematopoietic stem cell transplant (HSCT); subjects must be at least 100 days from HSCT at the time of screening and off immunosuppressant medication for at least 1 month at the time of screening, and have no active graft-vs-host disease (GVHD), orXx_NEWLINE_xXMore than 2 months out from allogenic hematopoietic stem cell transplant prior to randomization.Xx_NEWLINE_xXHematopoietic Stem Cell Transplant: Patients who have experienced their relapse after a HSCT are eligible, provided they have no evidence of Graft-versus-Host Disease (GVHD) and are at least 60 days post-transplant at the time of enrollment.Xx_NEWLINE_xXPatients after allogeneic stem cell transplantation from a related or unrelated, HLA-matched or mismatched donor with the diagnosis of transplant related microangiopathy. Patients having received any of the following stem cell sources are eligible: G-CSF mobilized peripheral blood stem cells, bone marrow, umbilical cord blood.Xx_NEWLINE_xXFor Pre-allo Part A (before stem cell transplant): Relapsed or refractory AML (greater than 5% blasts)Xx_NEWLINE_xXFor Pre-allo Part A (before stem cell transplant): Eligible for an allogeneic hematopoietic stem cell transplantXx_NEWLINE_xXFor Pre-allo Part A (before stem cell transplant): Partially matched donors (related or unrelated) and umbilical cord blood cells are excluded as the source of hematopoietic stem cellsXx_NEWLINE_xXFor Pre-allo Part A (before stem cell transplant): Prior alloSCTXx_NEWLINE_xXMust be relapsed or refractory after autologous stem cell transplant (ASCT) and/or 2 or more prior chemotherapy regimensXx_NEWLINE_xXReceived autologous stem cell transplant within 28 days or allogeneic transplant within 3 months prior to first dose of study drugXx_NEWLINE_xXPrior stem cell transplantXx_NEWLINE_xXStem cell transplant within previous 3 months prior to initiation of study therapyXx_NEWLINE_xXCurrent candidacy for a potentially curative allogeneic stem cell transplant, unless declinedXx_NEWLINE_xXAutologous bone marrow transplant or stem cell rescue within 4 months of study entryXx_NEWLINE_xXPrior autologous or allogeneic hematopoietic stem cell transplant (HSCT)Xx_NEWLINE_xXPrior allogeneic hematopoietic stem cell transplant.Xx_NEWLINE_xXPatients who are eligible, willing and able to receive an allogeneic stem cell transplant within 6 weeks are not eligibleXx_NEWLINE_xXPeripheral autologous stem cell transplant within 12 weeks prior to Baseline; prior allogeneic transplants within 16 weeks or chronic use of immunosuppressants.Xx_NEWLINE_xXPrior allogeneic hematopoietic stem cell transplant (HSCT)Xx_NEWLINE_xXPrior allogeneic hematopoietic stem cell transplantXx_NEWLINE_xXPrior autologous hematopoietic stem cell transplant within 90 days of study entryXx_NEWLINE_xXAll patients must have received at least one prior regimen for CLL, including cytotoxic chemotherapy, anti-CD20 monoclonal antibodies, a BTK inhibitor, or a PI3K inhibitor. Patients may have received high dose chemotherapy/autologous stem cell transplant (HDT/ASCT) or allogeneic hematopoietic stem cell transplant (allo SCT).Xx_NEWLINE_xXPrior allogeneic stem cell transplant in previous 3 monthsXx_NEWLINE_xXPatient must not be a candidate for an allo-hematopoietic stem cell transplant (HSCT)Xx_NEWLINE_xXSubjects with prior allogeneic transplant are excluded: however, subjects who have previously received an autologous stem cell transplant are allowed if a minimum of 100 days has elapsed from the time of transplant and the subject has recovered from transplant-associated toxicities prior to the first dose of GSK2816126Xx_NEWLINE_xXHistory of (or plans to undergo) spleen removal surgery or allogeneic stem cell transplantXx_NEWLINE_xXPatient must be:\r\n* >= 6 months since allogeneic bone marrow transplant prior to registration\r\n* Stem cell transplant or rescue without TBI: no evidence of active graft versus (vs) host disease and >= 3 months must have elapsed since transplantXx_NEWLINE_xXPatients must have progressive, relapsed or refractory disease after:\r\n* At least one prior systemic anti-lymphoma regimen (chemotherapy or immunotherapy except for transformed mycosis fungoides as described previously)\r\n* Relapsed or failed autologous or allogeneic stem cell transplantXx_NEWLINE_xXPrior autologous, peripheral stem cell transplant within 12 weeks of the first dose of study drug.Xx_NEWLINE_xXAutologous hematopoietic stem cell transplant or fludarabine chemotherapy within 6 months of study enrollmentXx_NEWLINE_xXHistory of allogeneic stem cell transplantXx_NEWLINE_xXHas previously received an organ or progenitor/stem cell transplant.Xx_NEWLINE_xXBack-up stem cell sourceXx_NEWLINE_xXPrior allogeneic stem cell transplantXx_NEWLINE_xXPrior autologous or allogeneic stem cell transplant (SCT)/bone marrow transplant within 12 months of signing the ICD. Subjects who received allogeneic SCT ? 12 months before signing the ICD may be eligible provided there is no ongoing graft-versus-host disease and no ongoing immune suppression therapy.Xx_NEWLINE_xXPrior allogeneic stem cell transplantXx_NEWLINE_xXTransformed lymphoma is included if patients are ineligible for (or refuse) hematopoietic stem cell transplantXx_NEWLINE_xXRelapsed/refractory diffuse large B cell lymphoma (DLBCL) is allowed if the patient is not eligible for, or refuses, hematopoietic stem cell transplantXx_NEWLINE_xXAt least 100 days after receiving any allogeneic hematopoietic stem cell transplant ANDXx_NEWLINE_xXPatient has received any stem cell agents (other than hematopoietic graft) during study participation or within 30 days prior to study entry.Xx_NEWLINE_xXPatient has participated or is currently participating in any bone marrow derived autologous and allogeneic stem cell or gene therapy study.Xx_NEWLINE_xXReceived autologous stem cell transplant (ASCT) within 12 monthsXx_NEWLINE_xXPatients <100 days since prior allogeneic stem cell transplantXx_NEWLINE_xXPrevious allogeneic hematopoietic stem cell transplant (HSCT transplant).Xx_NEWLINE_xXfrontline cytotoxic systemic therapy, for patients who are ineligible for stem cell transplant (SCT).Xx_NEWLINE_xXPatients with previous allogeneic stem cell transplant.Xx_NEWLINE_xXPrior myeloablative or non-myeloablative allogeneic hematopoietic stem cell transplant using either bone marrow or peripheral blood stem cells or single or double cord blood within 24 months.Xx_NEWLINE_xXParticipants with a history of allogeneic stem cell transplant are eligible for study participation provided the following eligibility criteria are met:Xx_NEWLINE_xXPrior bone marrow or stem cell transplant;Xx_NEWLINE_xXINCLUSION FOR AUTOLOGOUS STEM CELL COLLECTION (PHASE 1 - TRANSPLANT RECIPIENT):Xx_NEWLINE_xXINCLUSION CRITERIA TO PROCEED WITH AUTOLOGOUS STEM TRANSPLANT (PHASE 2 - TRANSPLANT RECIPIENT):Xx_NEWLINE_xXHas not received a prior hematopoietic stem cell transplant within the previous 3 monthsXx_NEWLINE_xXAllogeneic hematopoietic stem cell transplant or Donor Lymphocyte Infusion within 90 days prior to to the first dose of study drugXx_NEWLINE_xXPatients are eligible 12 weeks after myeloablative therapy with autologous stem cell transplant (timed from start of protocol therapy); patients must meet adequate bone marrow function definition post-myeloablative therapy; patients who received stem cell reinfusion following non-myeloablative therapy are eligible once they meet peripheral blood count criteria; patients status post-allogeneic stem cell transplant are excluded unless they are > 1 year post transplant, have been off all immunosuppressive therapy for more than 3 months and do not have active graft-versus-host disease (GVHD)Xx_NEWLINE_xXANC ? 1000/?l (? 500/?l after stem cell transplant)Xx_NEWLINE_xXHematopoietic Stem Cell Transplant: Patients who have had previous allogeneic HSCT must have grade I or less of Graft-versus-Host Disease (GVHD) and have not received immunosuppressive medication for at least 90 days.Xx_NEWLINE_xXAML patients who are candidates for allogeneic stem cell transplant are excluded.Xx_NEWLINE_xXPatient with a prior stem cell transplant (both autologous and allogeneic)Xx_NEWLINE_xXEligible for autologous stem cell transplantXx_NEWLINE_xXPrior allogeneic hematopoietic stem cell transplantXx_NEWLINE_xXPrior allogeneic hematopoietic stem cell transplant within </=4 months before first dose of study drug (Subjects must have completed immunosuppressive therapy before enrollment.Xx_NEWLINE_xXPrevious allogeneic stem cell transplant is allowed only if subjects are >100 days from stem cell transplant and do not have uncontrolled acute or chronic graft-vs-host diseaseXx_NEWLINE_xXParticipant’s disease has relapsed after, is refractory to induction and/or salvage therapy, or has relapsed after hematopoietic stem cell transplant (HSCT)Xx_NEWLINE_xXPatients must be within 30 – 120 days after hematopoietic stem cell transplant (HSCT)Xx_NEWLINE_xXPrevious autologous stem cell collectionXx_NEWLINE_xXPatients with previous allogeneic stem cell transplant (SCT) if they meet either of the following criteria: < 100 days from allogeneic SCT, acute or chronic graft-versus-host disease (GvHD), or receiving immunosuppressive therapy as treatment for or prophylaxis against GvHD within the last 7 daysXx_NEWLINE_xXAutologous or allogeneic stem cell or bone marrow transplant within 3 months prior to first dose of study drug.Xx_NEWLINE_xXHas received an allogeneic bone marrow or allogeneic stem cell transplant.Xx_NEWLINE_xXSubject has had hematopoietic stem cell transplant (HSCT) and meets any of the following:Xx_NEWLINE_xXAutologous or allogeneic stem cell or bone marrow transplant within 3 months prior to first dose of study treatment.Xx_NEWLINE_xXAutologous bone marrow transplant or stem cell rescue within 4 months of study entryXx_NEWLINE_xXPrior allogeneic stem cell transplant, except for a specific cohortXx_NEWLINE_xXPatients who are candidates for hematopoietic stem cell transplantXx_NEWLINE_xXPatients who have received a prior autologous stem cell transplant are eligible if the transplant occurred > 6 months ago.Xx_NEWLINE_xXPatients who have received a prior allogeneic stem cell transplant are eligible if:Xx_NEWLINE_xXPrior organ or allogeneic stem cell transplantXx_NEWLINE_xXSubject has undergone an allogeneic stem cell transplantXx_NEWLINE_xXAt least one prior therapy; patients with newly diagnosed tNHL are eligible at the time of transformation; prior autologous stem cell transplant is allowedXx_NEWLINE_xXPatients eligible for and willing to undergo autologous stem cell transplant with curative intent at the time of enrollment are not eligibleXx_NEWLINE_xXPatients that received an autologous stem cell transplant must be at least 3 months post-transplant and recovered from acute transplant-related toxicities.Xx_NEWLINE_xXAllogeneic stem cell transplant (SCT)Xx_NEWLINE_xXAllogeneic stem cell transplant within 60 days, active acute or chronic graft-versus-host disease (GvHD), or receiving immunosuppressive therapy as treatment for GvHDXx_NEWLINE_xXSubjects must have received >= 2 prior regimens for relapsed disease; induction therapy and stem cell transplant will be considered as one regimenXx_NEWLINE_xXPrior treatment with hematopoietic stem cell transplantXx_NEWLINE_xXNeed for cytoreduction prior to allogeneic stem cell transplant.Xx_NEWLINE_xXPatient with diffuse large B cell lymphoma has received or is ineligible for autologous or allogeneic stem cell transplant.Xx_NEWLINE_xXNo more than 4 prior lines of systemic anti-cancer therapy and no prior bone marrow transplant or stem cell transplant within 12 months of dosing, and no prior allogeneic transplant.Xx_NEWLINE_xXPatients are not eligible post allogeneic stem cell transplant.Xx_NEWLINE_xXThe patient is not considered to be an immediate candidate for allogeneic stem cell transplant as determined by the investigator.Xx_NEWLINE_xXCompletion of autologous stem cell transplant (SCT) within 100 days prior to Cycle 1 Day 1Xx_NEWLINE_xXAutologous or allogeneic stem cell transplant within 3 months prior to enrolment [NOTE: subjects with evidence of active graph versus host disease are excluded].Xx_NEWLINE_xXPrior allogeneic hematopoietic cell transplantXx_NEWLINE_xXHistory of allogeneic stem cell transplantXx_NEWLINE_xXNot currently a candidate for allogeneic hematopoietic stem cell transplant (HSCT).Xx_NEWLINE_xXPrior allogeneic stem cell transplant patients will be allowed to enroll if they are past day +100 of transplant, have no active graft-versus-host-disease, are not on any immunosuppressants and have been off immunosuppressants for at least 4 weeks; prior autologous stem cell transplant patients will also be allowed to enter this study if they are past their day +100 of transplantXx_NEWLINE_xXReceived an allogeneic stem cell transplant <3 months prior to the first dose of study medication, or presence of polymerase chain reaction (PCR)-detectable cytomegalovirus (CMV) in any post-allogeneic transplant participantXx_NEWLINE_xXPrior autologous hematopoietic stem cell infusion <4 weeks prior to first study doseXx_NEWLINE_xXPrior peripheral stem cell transplant within 12 weeks of the first dose of study treatmentXx_NEWLINE_xXPatients must have recovered from the acute side effects of all prior anticancer therapy\r\n* At least 1 week from prior cytotoxic chemotherapy\r\n* At least 4 weeks from craniospinal irradiation\r\n* At least 4 months since hematopoietic stem cell transplant (HSCT) with no evidence of active graft-versus-host disease (GVHD)Xx_NEWLINE_xXPatient either is not a candidate for autologous stem cell transplant (ASCT), has declined the option of ASCT, or has relapsed after prior ASCT.Xx_NEWLINE_xXPrior peripheral autologous stem cell transplant within 12 wks of Baseline.Xx_NEWLINE_xXPrior allogeneic stem cell transplant.Xx_NEWLINE_xXSubjects who received an allogeneic bone marrow or allogeneic peripheral blood stem cell transplantXx_NEWLINE_xXSubjects who are planning for or who are eligible for stem cell transplantXx_NEWLINE_xXPrior stem cell transplantXx_NEWLINE_xXpatients with Stem Cell Transplant (SCT) or Rescue without TBI: Evidence of active graft vs. host disease and < 3 months since SCTXx_NEWLINE_xXPrior allogeneic stem cell transplant more than 6 months from the first transplant, in remissionXx_NEWLINE_xXPrior autologous or allogeneic hematopoietic stem cell transplantXx_NEWLINE_xXReceived any previous autologous stem cell transplant at least 12 weeks (3 months) prior.Xx_NEWLINE_xXStem Cell Transplant or Rescue: No evidence of active graft vs. host disease and >= 2 months must have elapsedXx_NEWLINE_xXPrior peripheral stem-cell transplant within 12 weeks of the first dose of elotuzumab.Xx_NEWLINE_xXPrior autologous bone marrow or peripheral stem cell transplant less than 3 months prior to enrollment.Xx_NEWLINE_xXPatients must have biopsy proven relapse of a solid tumor or leukemia (for diseases outlined); patients with solid tumors must have failed an autologous transplant or be considered ineligible to receive an autologous transplant because of organ dysfunction or inability to obtain a suitable autologous stem cell collection; in addition, patients will be eligible if their attending physician and transplant physician agree that autologous transplantation would not offer a significant chance of cure (i.e. > 20%); patients with solid tumors must be in complete remission or have minimal residual disease prior to transplant; patients with bulky disease (any single tumor mass measuring > 5 cm in greatest diameter) will not be eligible for this study; select patients with very high-risk solid tumors will be eligible in first complete or partial remission, as indicated below; all subjects with solid tumors who have not had stem cells collected for clinical purposes prior to enrolling on the study will undergo autologous stem cell harvest following standard clinical procedures before beginning the study conditioning regimenXx_NEWLINE_xXPatients < 65 years of age with histologically confirmed refractory or relapsed Hodgkin’s disease (including patients who fail or relapse after autologous stem cell transplant [SCT]); this upper age limit will apply to transplants from both matched related and unrelated donorsXx_NEWLINE_xXSubject may not have had hematopoietic stem cell transplant (HSCT) meeting any of the following: \r\n* Is within 2 months of transplant from cycle 1 day 1 (C1D1) \r\n* Has clinically significant graft-versus-host disease requiring treatment\r\n* Has >= grade 2 persistent non-hematological toxicity related to the transplant \r\n* Donor lymphocyte infusion (DLI) is not permitted < 30 days prior to study registrationXx_NEWLINE_xXPatients who at the time of enrollment, are willing and eligible to receive a stem cell transplant will not be eligible to participate in this studyXx_NEWLINE_xXFor post autologous stem cell transplant (ASCT) patients, salvage therapy plus ASCT just prior to MDV9300 treatment must have resulted in a PR or stable disease;Xx_NEWLINE_xXHistory of allogeneic stem cell transplant or transplant eligibleXx_NEWLINE_xXPatients with previous allogeneic stem cell transplant (SCT) within 6 months or with active acute or chronic graft-versus host disease are excluded; patients must be off immunosuppression for graft-versus host disease (GVHD) for at least 30 days before cycle 1 day 1Xx_NEWLINE_xXHematopoietic stem cell transplant recipients with chronic thrombocytopenia due to chronic graft-versus-host disease (GVHD) or other causesXx_NEWLINE_xXHematopoietic stem cell transplant recipient within 100 days post-transplantXx_NEWLINE_xXPrior autologous stem cell transplant (ASCT) within 6 months or prior ASCT at any time without full hematopoietic recovery before Cycle 1 Day 1, or allogeneic stem cell transplant any time.Xx_NEWLINE_xXPatients who have had an allogeneic stem cell transplant are excludedXx_NEWLINE_xXAny previous allogeneic hematopoietic stem cell transplant.Xx_NEWLINE_xXPrior autologous stem cell transplant (ASCT) within 6 months or prior ASCT at any time without full hematopoietic recovery before Cycle 1 Day 1 or allogeneic stem cell transplant any time.Xx_NEWLINE_xXPRE-STEM CELL TRANSPLANT (SCT)Xx_NEWLINE_xXStem cell source: bone marrow, peripheral blood stem cellXx_NEWLINE_xXPrior allogenic stem cell or solid organ transplantXx_NEWLINE_xXPhase II: Received an autologous or allogeneic stem cell transplant at the Hospital of the University of Pennsylvania and experienced a sentinel event of either 1) disease relapse, 2) severe (grade III or IV) graft-versus-host disease, or 3) unplanned hospital admission with length of stay greater than 72 hoursXx_NEWLINE_xXSubjects must be undergoing autologous or allogeneic hematopoietic cell transplant (HSCT) with the BEAM conditioning regimen prior to HSCTXx_NEWLINE_xXPatients undergoing myeloablative allogenic hematopoietic stem cell transplant for any indication (both malignant and non-malignant) are eligibleXx_NEWLINE_xXPrior therapies: Patients undergoing stem cell transplant of any kindXx_NEWLINE_xXPatients must have received allogeneic hematopoietic stem cell transplant and be greater than 30 days post-transplant at the time of registrationXx_NEWLINE_xXAppropriate third party payer coverage for \Homebound Stem Cell Transplant Program\Xx_NEWLINE_xXPlanned stem cell transplantXx_NEWLINE_xXScheduled to undergo an allogeneic hematopoietic stem cell transplant for any cancer or non-cancer illnessXx_NEWLINE_xXPatients must have a plan to receive a CD34-selected peripheral blood stem cell transplant with TBI-based conditioningXx_NEWLINE_xXScheduled to undergo a hematopoietic stem cell transplant for any cancer or non-cancer illness from any autologous, related or unrelated donor source including bone marrow, peripheral blood progenitor cell, or umbilical cord bloodXx_NEWLINE_xXPatients receiving myeloablative chemotherapy in preparation for allogeneic or autologous bone marrow or stem cell transplantXx_NEWLINE_xXPatient within 100 days of autologous/allogeneic (auto/allo) stem cell transplant and their stem cell physician does not approve yogurt ingestionXx_NEWLINE_xXPatients may have received a prior allogeneic hematopoietic stem cell transplant (alloHSCT) for any indication and from any donor; patients developing cGvHD after donor lymphocyte infusion (DLI) are also eligibleXx_NEWLINE_xXONCOLOGY PATIENTS: patients with an oncology diagnosis that are or will be on a chemotherapy regimen that will last for an additional >= 3 months or are on or will be on a chemotherapy regimen for < 3 months and then proceed to transplant (allogeneic or autologous stem cell rescue) during the 3-month study periodXx_NEWLINE_xXPatients who have undergone prior stem cell transplant will not be excluded from study entry as long as adequate marrow reserve is demonstrated (refer to hematologic parameters)Xx_NEWLINE_xXPrior allogeneic hematopoietic stem cell transplant (HSCT)Xx_NEWLINE_xXPlanned allogeneic stem cell transplant with schedule that accommodates at least a 5 week exercise intervention, but not greater than 12 weeksXx_NEWLINE_xXAllogeneic hematopoietic cell transplant recipientXx_NEWLINE_xXAllogenic bone marrow transplant or stem cell rescue within 4 months before first dose of study drug; patients must have completed immunosuppressive therapy before enrollmentXx_NEWLINE_xXPatients planned for upfront consolidation with high-dose therapy and autologous stem cell transplantXx_NEWLINE_xXPatients with DLBCL: Cancer progression after transplant, or be unwilling, unable or not an appropriate candidate for an autologous stem cell or bone marrow transplantXx_NEWLINE_xXNOTE: Prior autologous stem cell transplant as well as prior radiation to CNS does NOT prevent patients from enrollment into the trialXx_NEWLINE_xXPatient has undergone prior allogenic stem cell transplant (autologous stem cell transplant is NOT an exclusion)Xx_NEWLINE_xXParticipants must have acute GVHD as defined by the clinical impression of the treating physician; biopsy of the involved tissue, while encouraged, is not required for study entry; eligibility includes:\r\n* Acute GVHD developing after allogeneic hematopoietic stem cell transplantation using bone marrow, peripheral blood stem cells, or umbilical cord blood; recipients of non-myeloablative, reduced intensity and myeloablative transplants are eligible\r\n* Patients who develop acute GVHD after donor lymphocyte infusion (DLI) are eligible\r\n* There is no specified time window after day 0 of transplant as acute GVHD is only defined by clinical manifestations\r\n* Patients must have experienced neutrophil engraftment after hematopoietic cell transplant (HCT) as defined by absolute neutrophil counts >= 500/ul x 3 consecutive measurementsXx_NEWLINE_xXPrior allogeneic hematopoietic cell transplantXx_NEWLINE_xXEnrollment in any other mucositis prevention study from screening up to day 45 post-stem cell transplantXx_NEWLINE_xXPatients with a prior stem cell transplant (SCT) must have failed the SCTXx_NEWLINE_xXPediatric patients admitted to the hospital for a stem cell transplantXx_NEWLINE_xXPatients admitted to the transplant unit for autologous stem cell transplant, donor lymphocyte infusions, mesenchymal cell infusions, a second stem cell transplant, graft versus host disease or other complications post SCT will not be includedXx_NEWLINE_xXEnglish speaking parents of children ages 7 to 17 years who are admitted to the hospital for a stem cell transplantXx_NEWLINE_xXParents of children admitted to the transplant unit for autologous stem cell transplant, donor lymphocyte infusions, mesenchymal cell infusions, a second stem cell transplant, graft versus host disease or other complications post SCT will not be includedXx_NEWLINE_xXScheduled to undergo either autologous or allogeneic hematopoietic stem cell transplantXx_NEWLINE_xXPrior myeloablative or non-myeloablative allogeneic hematopoietic stem cell transplant using either bone marrow or peripheral blood stem cells within 12 monthsXx_NEWLINE_xXPatients with previous hematopoietic stem cell transplant (HSCT)Xx_NEWLINE_xXPatient must be scheduled to undergo allogeneic hematopoietic stem cell transplant (HSCT) (adults or pediatric patients) or autologous HSCT (pediatric patients only) and be at high risk or very high risk of developing veno-occlusive disease (VOD).Xx_NEWLINE_xXPrior autologous or allogeneic hematopoietic stem cell transplantXx_NEWLINE_xXPlanned post-transplant maintenance therapy except for FLT3 inhibitors or TKIs must be declared prior to randomization. If it is known prior to enrollment that the hematopoietic stem cell product will need to be cryopreserved, the patient should not be enrolled.Xx_NEWLINE_xXNon-allogeneic (e.g. autologous) or syngeneic hematopoietic stem cell transplant (SCT) recipientsXx_NEWLINE_xXNon-allogeneic (e.g. autologous) or syngeneic hematopoietic stem cell transplant (SCT) recipientsXx_NEWLINE_xXPeripheral blood stem cells must have been used as the stem cell sourceXx_NEWLINE_xXMust be candidates for peripheral blood stem cell transplants.Xx_NEWLINE_xXHas previously received an allogenic hematopoietic stem cell transplant.Xx_NEWLINE_xXAdmission to the University of North Carolina (UNC) Hospital Bone Marrow Transplant Unit for allogeneic stem cell transplantXx_NEWLINE_xXDiagnosis of acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) for whom an allogeneic hematopoietic stem cell transplant using a reduced intensity conditioning is planned or has been performed and patient is prior to day 100 post-transplantXx_NEWLINE_xXPrior solid organ or stem cell transplantXx_NEWLINE_xXPrior allogeneic or autologous hematopoietic stem cell transplant in past 12 monthsXx_NEWLINE_xXPatients who have undergone a non-myeloablative stem cell transplant must have > 65% donor lymphoid hematopoiesis within 30 days of study enrollmentXx_NEWLINE_xXELIGIBILITY FOR CD34 SELECTED STEM CELL INFUSION FOLLOWING PRIOR ALLOGENEIC STEM CELL TRANSPLANT (MAY BE REFERRED TO AS A \BOOST\)Xx_NEWLINE_xXPatient must have a diagnosis that is managed with an alternative donor allogeneic hematopoietic cell transplantXx_NEWLINE_xXPrior allogeneic stem cell transplantXx_NEWLINE_xXHistory of an allogeneic stem cell transplant. Subjects with a history of an autologous stem cell transplant are NOT excluded if they meet inclusion criteria related to history of autologous stem cell transplant.Xx_NEWLINE_xXPrior autologous stem cell transplant (ASCT) ? 3 months before first dose.Xx_NEWLINE_xXPrior allogeneic stem cell transplant with either standard or reduced intensity conditioning.Xx_NEWLINE_xXAutologous hematopoietic stem cell transplant < 3 months prior to enrollment.Xx_NEWLINE_xXPrior allogeneic hematopoietic stem cell transplant.Xx_NEWLINE_xXMore than 12 weeks post-transplant of your own blood forming stem cells (autologous transplant)Xx_NEWLINE_xXPrior allogenic stem cell or solid organ transplantXx_NEWLINE_xXPrior treatment with any adoptive T cell therapy; prior hematopoietic stem cell transplant (HSCT) is allowedXx_NEWLINE_xXHas documented seropositivity for CMV within 1 year before hematopoietic stem cell transplant (HSCT)Xx_NEWLINE_xXReceiving first allogeneic HSCT (bone marrow, peripheral blood stem cell, or cord blood transplant)Xx_NEWLINE_xXPlanned haematopoietic stem cell transplant (HCT) during the study period. (If a HCT occurred prior to enrolment in the study, the subject may not receive study vaccine until at least 50 days after the transplant procedure).Xx_NEWLINE_xXPrior allogeneic stem cell or solid organ transplantXx_NEWLINE_xXSuitable candidate for therapy with high-dose chemotherapy and autologous stem cell transplant (ASCT) as determined by the treating physicianXx_NEWLINE_xXDONOR: Donors undergoing stem cell collection for match related allogeneic stem cell transplantXx_NEWLINE_xXSubjects planning to undergo allogeneic stem cell transplant within 6 months of enrollmentXx_NEWLINE_xXPrevious allogeneic hematopoietic stem cell transplant within 6 months prior to enrollment, active graft versus host disease (GVHD), or requiring transplant-related immunosuppression.Xx_NEWLINE_xXPrior autologous or allogeneic stem cell transplant within defined period of initiation of therapyXx_NEWLINE_xXPrior allogeneic stem cell transplant with active graft-versus-host- disease (GVHD).Xx_NEWLINE_xXPreviously received an allogeneic stem cell transplant and the occurrence of one or more of the following: received the transplant within 6 months prior to study day 1;received immunosuppressive therapy within the last 3 months prior to study day 1;having signs or symptoms of acute or chronic graft-versus-host disease.Xx_NEWLINE_xXAutologous stem cell transplant < 90 days prior to study day 1.Xx_NEWLINE_xXPatients with a history of organ transplant including high dose chemotherapy with autologous stem cell rescueXx_NEWLINE_xXParticipant is candidate for hematopoietic stem cell transplants at the time of enrollment.Xx_NEWLINE_xXRecipient of a stem cell or bone marrow transplant.Xx_NEWLINE_xXPrior autologous stem cell transplant (ASCT) within 6 months preceding Cycle 1 Day 1.Xx_NEWLINE_xXPrior allogeneic stem cell transplant and/or chimeric antigen receptor T-cell therapy at any time.Xx_NEWLINE_xXHave received allogeneic stem cell transplant.Xx_NEWLINE_xXPrior allogeneic stem cell transplant, no evidence of active graft-versus host disease (GVHD) and must be ? 2 weeks off immunosuppressive therapy.Xx_NEWLINE_xXThe patient underwent autologous or allogeneic stem cell transplant within 60 days prior to receiving the first dose of omacetaxine and has any evidence of ongoing graft versus host disease (GVHD), or GVHD requiring immunosuppressive therapy.Xx_NEWLINE_xXPatients with prior autologous hematopoietic stem cell transplant who, in the investigator's judgment, have not fully recovered from the effects of the last transplant (e.g., transplant related side effects).Xx_NEWLINE_xXPrior allogeneic hematopoietic stem cell transplant (HSCT) with either standard or reduced intensity conditioning ? 6 months prior to starting CC-90009.Xx_NEWLINE_xXStem cell transplant within the past 3 monthsXx_NEWLINE_xX